

### REMARKS

Claims 1, 3, 8-17, 19-20, 24-32, 34-37 and 39-50 are pending the subject application. Claim 2, 4-7, 18, 21-23, 33, 38 and 51-54 have been canceled. No claims have been indicated to be allowable.

Applicants' wishes to thank Examiner Maewall and her Supervisor for the personal interview held at the United States Patent and Trademark Office on April 21, 2009 with Applicant Gary J. Calton and Beverly J. Artale, Esq. During the interview, Applicants explained the differences between their invention and the inventions disclosed in Lowery et al and Ukai et al. references. Possible amendments to the claims to overcome the teaching of these prior art references alone or in combination were also discussed. No agreement was reached during the interview.

### 35 USC 103

Claims 1-3 and 5-54 stand rejected under 35 USC 103 (a) as being unpatentable over Lowry et al (US PG PUB 20020007878) in view of Ukai et al. (JP 411228450A). This rejection is respectfully traversed.

Briefly, Applicants' claims, as now amended, recite a method of inhibiting the undesirable taste of an amino acid component in an orally administrable composition, and to orally administrable amino acid containing compositions used in the method. The method comprises adding a carrageenan to the amino acid containing composition in a specified amount which is effective to mask the undesirable taste of the amino acid component. Oral compositions comprising at least one amino acid and carrageenan are also claimed by Applicants.

The Examiner has relied upon the Lowry et al. reference to teach a nutritional product comprising an amino acid, i.e. L-arginine, for a person having renal failure.

the two references is impermissible hindsight motivation based on Applicant's own disclosure.

For reasons as stated herein above, both Lowry et al or Ukai et al, taken alone or in combination, fail to render obvious Applicants' invention as now claimed. Accordingly, this rejection is improper and should now be withdrawn.

Claims 1-3, 8-20, 24-37 and 39-54 stand rejected under 35 USC 103 (a) as being unpatentable over Ukai et al. (JP 411228450A) in view of Acosta et al (U.S. Patent 5, 550,146). This rejection is respectfully traversed.

For reasons as stated herein above, Ukai et al. fails to teach or in any way suggest an **amino acid component or the use of a carageenan** (or any other masking agent for that matter) **to mask the strong fishy flavor specific to an amino acid component**. Herein again, amino acids not only possess a bitter taste but a **strong fishy flavor** which is difficult to mask. Consequently, Ukai et al. fails to render obvious Applicants' invention as now claimed.


To cure the deficiencies of the Ukai et al. the Examiner has relied on Acosta et al. to evidence that amino acids are known in the art to have a bitter taste. Acosta discloses a nutritional formula which uses specific free amino acids to provide the source of amino nitrogen. Acosta is silent with respect to the use of a carrageenan to mask the taste of an amino acid. The Examiner has alleged that Acosta teaches that it is known in the art that amino acids have a bitter taste. Applicants admit that it is known that amino acids have a bitter taste. Applicants go further to evidence ( see Sarama et al, ) that amino acids not only have a **bitter taste** but a characteristic **foul fishy odor** as well that is difficult to mask especially in large amounts generally used for medicinal purposes. Clearly, neither of the references teaches or suggest the requisite motivation to lead one skilled in the arts to have a **reasonable expectation** that the **distinct foul fishy amino acid odor** can be masked by a carrageenan in the amount as claimed by Applicants.

While obviousness does not require absolute predictability, it does require a **reasonable expectation of success**. One cannot base a determination of obviousness on what the skilled person **might try** or find **obvious to try**. Rather, the proper test of

obviousness requires determining **what the prior art would have led the skilled person to do.**

For reasons as stated herein above, it is believed that Applicants' invention as now claimed is patentable over the herein cited prior art. Accordingly, allowance of claims 1, 3, 8-17, 19-20, 24-32, 34-37 and 39-50 of the subject application is requested.

Respectfully submitted,



Beverly J. Artale  
Attorney for Applicants  
Reg. No. 32,366

Tel: (410) 531-4769  
3826 Sunflower Circl.  
Suite 001  
Mitchellville, Maryland 20721

**USPTO PATENT FULL-TEXT AND IMAGE DATABASE**[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)[Add to Cart](#)[Images](#)

( 1 of 1 )

**United States Patent**  
**Sarama , et al.****6,794,375**  
**September 21, 2004****Palatable arginine compounds and uses thereof for cardiovascular health****Abstract**

The present invention is directed to a compound having the structure (I): and acceptable salts, polypeptides, and pro-forms thereof, wherein R is selected from the group consisting of: (a) substituted glycerols; wherein n is an integer from 1 to 2; (b) vitamins; wherein n is 1; (c) sterols; wherein n is 1; (d) stanols; wherein n is 1; and (e) C.sub.6 -C.sub.32 alkyl; and (f) C.sub.6 -C.sub.32 alkenyl; wherein n is 1. The present invention is further directed to compositions and kits comprising these compounds as well as methods of using the compounds. The compounds, compositions, kits, and methods herein are useful for providing general health benefits to the consumer, particularly cardiovascular benefits, anti-menopausal benefits and/or treating sexual dysfunction (particularly, erectile dysfunction). Most particularly, the compounds, compositions, kits, and methods herein are useful for providing cardiovascular benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, thrombosis) and, for example, treating other conditions such as hypercholesterolemia, hypertension, poor circulation, ##STR1## and complications associated with diabetes.

**Inventors:** **Sarama; Robert Joseph** (Loveland, OH), **Niehoff; Raymond Louis** (West Chester, OH)  
**Assignee:** **The Procter & Gamble Co.** (Cincinnati, OH)  
**Appl. No.:** **10/181,655**  
**Filed:** **July 19, 2002**  
**PCT Filed:** **January 25, 2001**  
**PCT No.:** **PCT/US01/02384**  
**PCT Pub. No.:** **WO01/55098**  
**PCT Pub. Date:** **August 02, 2001**

**Current U.S. Class:****514/182 ; 426/72; 426/73****Current International Class:****A23G 1/00 (20060101); A23L 1/305 (20060101); A23L**

1/30 (20060101); A23L 1/308 (20060101); A61K 031/56 ();  
A23L 001/302 ()

**Field of Search:**

552/544 514/182 426/72,73

---

**References Cited [Referenced By]**

---

**U.S. Patent Documents**

<u>2661349</u>	December 1953	Caldwell et al.
<u>3004043</u>	October 1961	Stern
<u>3085939</u>	April 1963	Wruble et al.
<u>3455838</u>	July 1969	Marotta et al.
<u>3579548</u>	May 1971	Whyte
<u>3751569</u>	August 1973	Erickson
<u>3865939</u>	February 1975	Jandacek
<u>4195084</u>	March 1980	Ong
<u>4338346</u>	July 1982	Brand
<u>4399163</u>	August 1983	Brennan et al.
<u>4411925</u>	October 1983	Brennan et al.
<u>4420432</u>	December 1983	Chibata et al.
<u>4423029</u>	December 1983	Rizzi
<u>4455333</u>	June 1984	Hong et al.
<u>4460617</u>	July 1984	Barndt et al.
<u>4524067</u>	June 1985	Arichi et al.
<u>4582715</u>	April 1986	Volpenhein
<u>4582927</u>	April 1986	Fulcher
<u>4599152</u>	July 1986	Ashmead
<u>4602003</u>	July 1986	Malinow
<u>4680290</u>	July 1987	Cassal
<u>4705690</u>	November 1987	Brand et al.
<u>4705691</u>	November 1987	Kupper et al.
<u>4737375</u>	April 1988	Nakel et al.
<u>4786510</u>	November 1988	Nakel et al.
<u>4786518</u>	November 1988	Nakel et al.
<u>4830716</u>	May 1989	Ashmead
<u>4863898</u>	September 1989	Ashmead et al.
<u>4920098</u>	April 1990	Cotter et al.
<u>4946701</u>	August 1990	Tsai et al.
<u>4994283</u>	February 1991	Mehansho et al.
<u>5032608</u>	July 1991	Dudrick
<u>5108761</u>	April 1992	Andon et al.
<u>5112815</u>	May 1992	Ambrus et al.
<u>5118513</u>	June 1992	Mehansho et al.

<u>5128374</u>	July 1992	Kochanowski
<u>5151274</u>	September 1992	Saltman et al.
<u>5157022</u>	October 1992	Barbul
<u>5186965</u>	February 1993	Fox et al.
<u>5215769</u>	June 1993	Fox et al.
<u>5217997</u>	June 1993	Levere et al.
<u>5225221</u>	July 1993	Camden et al.
<u>5232709</u>	August 1993	Saltman et al.
<u>5244887</u>	September 1993	Straub
<u>5270041</u>	December 1993	Eugster et al.
<u>5306514</u>	April 1994	Letton et al.
<u>5306515</u>	April 1994	Letton et al.
<u>5314919</u>	May 1994	Jacobs
<u>5364884</u>	November 1994	Varma et al.
<u>5385940</u>	January 1995	Moskowitz
<u>5389387</u>	February 1995	Zuniga et al.
<u>5401524</u>	March 1995	Burkes et al.
<u>5419925</u>	May 1995	Seiden et al.
<u>5422128</u>	June 1995	Burkes et al.
<u>5422131</u>	June 1995	Elsen et al.
<u>5424082</u>	June 1995	Dake et al.
<u>5427806</u>	June 1995	Ekanayake et al.
<u>5428070</u>	June 1995	Cooke et al.
<u>5433965</u>	July 1995	Fischer et al.
<u>5445837</u>	August 1995	Burkes et al.
<u>5451416</u>	September 1995	Johnston et al.
<u>5468506</u>	November 1995	Andon
<u>5474793</u>	December 1995	Meyer et al.
<u>5571441</u>	November 1996	Andon et al.
<u>5591836</u>	January 1997	Mazur et al.
<u>5612026</u>	March 1997	Diehl
<u>5670344</u>	September 1997	Mehansho et al.
<u>5780039</u>	July 1998	Greenberg et al.
<u>5843499</u>	December 1998	Moreau et al.
<u>5958913</u>	September 1999	Miettenen et al.
<u>6063428</u>	May 2000	Ekanayake et al.

#### Foreign Patent Documents

197 50 422	Nov., 1998	DE
198 00 812	Jul., 1999	DE
0 168 112	Jan., 1986	EP
0 289 636	Nov., 1988	EP

0 320 976	Jun., 1989	EP
0 546 796	Jun., 1993	EP
0 567 433	Oct., 1993	EP
58134197	Aug., 1983	JP
58203982	Nov., 1983	JP
9241156	Sep., 1997	JP
11193264	Jul., 1999	JP
2000128725	May., 2000	JP
WO 94/06450	Mar., 1994	WO
WO 94/18225	Aug., 1994	WO
WO 95/01172	Jan., 1995	WO
WO 95/08342	Mar., 1995	WO
WO 96/34858	Nov., 1996	WO
WO 97/42830	Nov., 1997	WO
WO 98/01126	Jan., 1998	WO
WO 98/06405	Feb., 1998	WO
WO 98/28990	Jul., 1998	WO
WO 99/30576	Jun., 1999	WO

### Other References

US 4,461,762, 7/1984, Malinow (withdrawn) .  
 XP-000999672--"Diet and Coronary Heart Disease: Beyond Dietary Fats and Low-Denistiy-Lipoprotein Cholesterol"; Am. J. Clin. Nutr., 1994; 59(suppl):1117S-23S. .  
 XP-001000550--"Chemical Composition of Cassia Holosericae"; J. Pharm. Univ. Karachi; vol. 3, No. 2, pp. 101-104, 1985. .  
 XP-002165058--"Preparation of amino acids and peptide derivatives as chemokine receptor antagonists"; Chemical Abstracts, Columbus, Ohio, 131:102544, 1999. .  
 XP-002165059--"Enzymic synthesis of arginine-based cationic surfactants"; Chemical Abstracts, Columbus, Ohio, 130:339707, 1999. .  
 XP-002165061--"Cationic surfactant compositions"; Chemical Abstracts, Columbus, Ohio, 100:70352, 1984. .  
 XP002165062--"Inhibition of serine proteases by low molecular weight peptides and their derivatives"; Chemical Abstracts, Columbus, Ohio, 95:164539, 1981. .  
 XP-002165063--"Skin conditioners containing arginine derivatives"; Chemical Abstracts, Columbus, Ohio, 132:325831, 2000. .  
 XP-002165064--"Long chain arginine esters"; Chemical Abstracts, Columbus, Ohio, 132:339176, 2000. .  
 XP-002165065--WPI Abstract, AN-1997-021670. .  
 XP-002165066--WPI Abstract, AN-1997-508789. .  
 XP-002165167--"Vitamin E amino acid esters"; Chemical Abstracts, Columbus, Ohio, 100:210216. .  
 Kochhar, S.P.--"Influence of Processing on Sterols of Edible Vegetable Oils", Prog. Lipid Res., vol. 22, pp. 161-188..

*Primary Examiner:* Badio; Barbara P.

*Attorney, Agent or Firm:* Lorentz; Bryn T. Chuey; S. Robert

---

***Parent Case Text***

---

**REFERENCE TO PRIORITY APPLICATION**

The present invention is a 371 of PCT/US01/02384 filed Jan. 25, 2001 and claims priority to U.S. Provisional Application Serial No. 60/178,723, filed Jan. 28, 2000.

---

***Claims***

---

What is claimed is:

1. A composition comprising: (a) a compound having the structure: ##STR32##  
or salts, polypeptides, and pro-forms thereof, wherein R is selected from the group consisting of: (1) sterols; wherein n is 1; (2) stanols; wherein n is 1; and (b) at least one nutrient selected from the group consisting of vitamins and minerals, wherein the composition is a beverage composition which exhibits a pH of less than about 5 when the beverage composition is constituted with aqueous fluid.
  2. A composition according to claim 1 further comprising water.
  3. A composition according to claim 2 further comprising at least one component selected from the group consisting of fruit juice, tea solids, milk solids, fruit flavors, botanical flavors, and mixtures thereof.
  4. A composition according to claim 3 wherein at least one of the nutrients is selected from the group consisting of iron, zinc, copper, calcium, phosphorous, niacin, thiamin, folic acid, pantothenic acid, iodine, vitamin A, vitamin C, vitamin B.sub.2, vitamin B.sub.3, vitamin B.sub.6, vitamin B.sub.12, vitamin D, vitamin E and vitamin K.
  5. A composition according to claim 4 at least one of the nutrients is vitamin C.
  6. A kit comprising a composition according to claim 1 and information that the kit provides one or benefits selected from the group consisting of cardiovascular benefits and organoleptic benefits.
  7. A kit according to claim 6 where at least one benefit is a cardiovascular benefit.
- 

***Description***

---

**FIELD OF THE INVENTION**

The present invention relates to compounds, compositions, kits, and methods which are useful for providing various general health benefits including, but not limited to cardiac benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, thrombosis) and, treating conditions such as hypercholesterolemia,



hypertension, poor circulation, and complications associated with diabetes.

## BACKGROUND OF THE INVENTION

Cardiovascular conditions, including heart disease, hypercholesterolemia, hypertension, poor circulation, and complications associated with diabetes, are serious medical conditions which are leading causes of mortality in humans. Various regimens have been suggested for prevention and treatment of these conditions, including pharmaceutical, dietary, and exercise regimens. Notwithstanding, they remain among the most prevalent and serious of all medical conditions.

L-arginine is a natural amino acid which has been identified to provide certain general health benefits including, for example, cardiovascular benefits, such as lowering cholesterol in the consumer, and treating, preventing, and/or inhibiting heart disease and poor circulation. See e.g., Moskowitz, U.S. Pat. No. 5,385,940, assigned to The General Hospital Corp., issued Jan. 31, 1995; Sonaka et al., EP 0,546,796, assigned to Ajinomoto Co., published Jun. 16, 1993; Cotter et al., U.S. Pat. No. 4,920,098, assigned to Baxter International Inc., issued Apr. 24, 1990; Dudrick, U.S. Pat. No. 5,032,608, issued Jul. 16, 1991; Levere et al., U.S. Pat. No. 5,217,997, issued Jun. 8, 1993; Cooke et al., U.S. Pat. No. 5,428,070, assigned to Stanford University, issued Jun. 27, 1995; Chibata et al., U.S. Pat. No. 4,420,432, assigned to Tanabe Seiyaky Co., issued Dec. 13, 1983; Varma et al., U.S. Pat. No. 5,364,884, assigned to Baylor College of Medicine, issued Nov. 15, 1994; and Barbul, U.S. Pat. No. 5,157,022, issued Oct. 20, 1992.

The utility of L-arginine, particularly to advance cardiovascular health, is therefore well known in the art. However, as for any beneficial regimen, compliance must be assured in order to realize the various benefits thereof. Unfortunately, L-arginine and its close derivatives (including salts, polypeptides, and pro-forms) have a strong, bitter, and fishy flavor, making L-arginine generally unacceptable for use. This results in decreased compliance of a regimen involving L-arginine, and the requisite cardiovascular benefits are therefore not realized. Accordingly, to enhance compliance, it would be desirable to provide L-arginine in a form which diminishes and/or removes the unacceptable flavor associated with L-arginine.

Unfortunately, flavor improvement is typically associated with a decrease in the general health benefits of the component which is desired to be delivered. Additionally, because delivery of relatively large amounts of L-arginine is desirable (erg., about 3 grams to about 10 grams of L-arginine per dose), it becomes increasingly more difficult to mask the strong, bitter, and fishy flavor. Such difficulties manifest themselves in the marketplace, where it is understood that current products containing L-arginine are not acceptable to the consumer due to unacceptable flavor.

The present inventors have surprisingly discovered that the unacceptable flavor of L-arginine is significantly improved through esterification of the L-arginine with any of various components, which will be defined herein. Interestingly, and quite unexpectedly, the esterified L-arginine exhibits significantly improved flavor relative to L-arginine itself. The improvement has been found particularly significant, wherein the component is lipophilic in nature. Accordingly, such combination is acceptable to consumers which, more importantly, translates into improved regimen compliance and enhanced cardiovascular, and other health, benefits. Additionally, the in vivo hydrolysis products of the ester are biologically acceptable and, in many cases, provide unique health benefits which supplement those of L-arginine.

The foregoing findings are unexpected relative to the known literature. Accordingly, the present inventors have discovered compounds, compositions, and kits which provide general health benefits, including cardiovascular benefits. Relative to known products, compliance is improved and/or ensured

through use of such compositions because the flavor is acceptable to the consumer. The compositions are easily provided as a pharmaceutical, food, or beverage product (preferably, a food or beverage product) and may be delivered in kit form, wherein the kit has the further advantage of disseminating information to the consumer regarding various health benefits and dose regimens of the compounds and compositions.

## SUMMARY OF THE INVENTION

The present invention is directed to a compound having the structure: ##STR2##

and acceptable salts, polypeptides, and pro-forms thereof, wherein R is selected from the group consisting of: (a) substituted glycerols; wherein n is an integer from 1 to 2; (b) vitamins; wherein n is 1; (c) sterols; wherein n is 1; (d) stanols; wherein n is 1; (e) C.sub.6 -C.sub.32 alkyl; wherein n is 1; and (f) C.sub.6 -C.sub.32 alkenyl; wherein n is 1.

The present invention is further directed to compositions and kits comprising these compounds as well as methods of using the compounds. The compounds, compositions, kits, and methods herein are useful for providing general health benefits to the consumer, particularly cardiovascular benefits, anti-menopausal benefits and/or treating sexual dysfunction (particularly, erectile dysfunction). Most particularly, the compounds, compositions, kits, and methods herein are useful for providing cardiovascular benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, thrombosis) and, for example, treating other conditions such as hypercholesterolemia, hypertension, poor circulation, and complications associated with diabetes.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds, and compositions comprising such compounds, which are useful for providing general health benefits to the consumer, particularly cardiovascular benefits, anti-menopausal benefits and/or treating sexual dysfunction (particularly, erectile dysfunction). The invention herein is further directed to kits comprising the compounds and compositions and methods of their use to provide the foregoing general health benefits.

Publications, patents, and patent applications are referred to throughout this disclosure. All references cited herein are hereby incorporated by reference.

All percentages and ratios are calculated by weight unless otherwise indicated. All percentages and ratios are calculated based on the total composition unless otherwise indicated.

All component or composition levels are in reference to the active level of that component or composition, and are exclusive of impurities, for example, residual solvents or by-products, which may be present in commercially available sources.

Referred to herein are trade names for components including, but not limited to, certain fats, flavors, and other components. The inventors herein do not intend to be limited by materials under a certain trade name. Equivalent materials (e.g., those obtained from a different source under a different name or catalog (reference) number) to those referenced by trade name may be substituted and utilized in the compositions, kits, and methods herein.

In the description of the invention various embodiments and/or individual features are disclosed. As will be apparent to the ordinarily skilled practitioner, all combinations of such embodiments and features are

possible and can result in preferred executions of the present invention.

The compositions, methods, and kits herein may comprise, consist essentially of, or consist of any of the elements as described herein.

### Definitions

As used herein, "alkyl" is an unsubstituted or substituted, branched or unbranched, saturated hydrocarbon radical. Unless otherwise specified herein, alkyls have from 1 to about 32 carbon atoms; preferably from about 3 to about 30 carbon atoms; more preferably from about 6 to about 28 carbon atoms; and most preferably from about 6 to about 22 carbon atoms.

As used herein, "alkenyl" is an unsubstituted or substituted, branched or unbranched hydrocarbon radical having at least one olefinic bond. Unless otherwise specified herein, alkenyls have from 2 to about 32 carbon atoms; preferably from about 3 to about 30 carbon atoms; more preferably from about 6 to about 28 carbon atoms; and most preferably from about 6 to about 22 carbon atoms. Preferred alkenyls are .quadrature.-3-alkenyls having a double bond between carbon atoms 3 and 4 counting from the .quadrature. (distal) end of the alkenyl chain.

As used herein, "acylalkyl" is --C(O)-alkyl, wherein "C(O)" designates a carbon atom having a doubly bonded oxygen atom attached thereto.

As used herein, "acylalkenyl" is --C(O)-alkenyl, wherein "C(O)" designates a carbon atom having a doubly bonded oxygen atom attached thereto.

### Compounds of the Present Invention

The present invention is directed to compounds which are useful for providing general health benefits to the consumer, particularly cardiovascular benefits, anti-menopausal benefits and/or treating sexual dysfunction (particularly, erectile dysfunction). The invention herein is further directed to compositions and kits comprising the compositions and methods of their use to provide the foregoing general health benefits. Most particularly, the compositions, kits, and methods herein are useful for providing cardiovascular benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, thrombosis) and, for example, treating other conditions such as hypercholesterolemia, hypertension, poor circulation, and complications associated with diabetes.

The present compounds have the structure: ##STR3##

and acceptable salts, polypeptides, and pro-forms thereof, wherein R is selected from the group consisting of: (a) substituted glycerols; wherein n is an integer from 1 to 2; (b) vitamins; wherein n is 1; (c) sterols; wherein n is 1; (d) stanols; wherein n is 1; (e) C.sub.6 -C.sub.32 alkyl; wherein n is 1; and (f) C.sub.6 -C.sub.32 alkenyl; wherein n is 1.

For simplicity herein, the identical structure may be abbreviated as follows: ##STR4##

wherein, as used herein, it is understood that "Arg" represents L-arginine rather than the enantiomer D-arginine.

In discovering the present compounds, the present inventors have surprisingly found that the undesirable flavor of L-arginine is significantly diminished or removed through esterification with the components

defined herein. Without intending to be limited by theory, the present inventors have excitingly discovered that by increasing the lipophilic nature of L-arginine, the unpalatable flavor associated with free L-arginine (and salts, polypeptides, and pro-forms) is removed and/or diminished. The present esters are further particularly useful for delivering cardiovascular and other health benefits associated with L-arginine. Additionally, the compounds herein have been carefully selected such that the in vivo hydrolysis products provide additional health benefits, for example, added nutritional supplementation or further cardiovascular benefit. These surprising and unexpected results allow for enhanced delivery and compliance associated with ingestion of L-arginine, while additionally providing the health benefits associated with the hydrolysis products.

As defined herein, L-arginine (including salts, polypeptides, and pro-forms thereof) may be esterified with a component selected from substituted glycerols, vitamins, sterols, stanols, C.sub.6 -C.sub.32 alkyl, and C.sub.6 -C.sub.32 alkenyl. Each of these components is more particularly described below.

### L-Arginine

L-arginine and its salts, polypeptides, and pro-forms, schematically represented as a critical element of the above structure, is commonly known in the art. L-arginine is a natural amino acid which has been identified to provide certain general health benefits including, for example, cardiovascular benefits, including lowering cholesterol in the consumer, and treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, hypertension, poor circulation, and/or complications associated with diabetes. See e.g., Moskowitz, U.S. Pat. No. 5,385,940, assigned to The General Hospital Corp., issued Jan. 31, 1995; Sonaka et al., EP 0,546,796, assigned to Ajinomoto Co., published Jun. 16, 1993; Cotter et al., U.S. Pat. No. 4,920,098, assigned to Baxter International Inc., issued Apr. 24, 1990; Dudrick, U.S. Pat. No. 5,032,608, issued Jul. 16, 1991; Levere et al., U.S. Pat. No. 5,217,997, issued Jun. 8, 1993; Cooke et al., U.S. Pat. No. 5,428,070, assigned to Stanford University, issued Jun. 27, 1995; Chibata et al., U.S. Pat. No. 4,420,432, assigned to Tanabe Seiyaky Co., issued Dec. 13, 1983; Varma et al., U.S. Pat. No. 5,364,884, assigned to Baylor College of Medicine, issued Nov. 15, 1994; and Barbul, U.S. Pat. No. 5,157,022, issued Oct. 20, 1992.

The L-arginine utilized herein may be used in its free form or may be utilized as a polypeptide, a salt, and/or a pro-form. Preferably, the L-arginine is utilized in its free form or as a salt. The salt used herein should be an acceptable salt, i.e., a salt useful in pharmaceutical and/or food compositions, preferably food compositions. Because the L-arginine herein is esterified at the carboxylic acid site, the L-arginine salts herein will be anionic salts, i.e., salts formed at any basic (e.g., amino) group. Salts of L-arginine are well-known in the art. For example, organic salts such as phosphate, citrate, acetate, malate, tartrate, fumarate, adipate, and lactate, as well as inorganic salts such as hydrochloride and hydrobromide may be utilized.

Polypeptides of L-arginine are also well-known in the art. Preferred polypeptides for use herein include those which are readily hydrolyzed in vivo to provide free L-arginine, or the L-arginine esterified as defined herein. Dipeptides and tripeptides of L-arginine are particularly preferred.

Pro-forms of L-arginine may also be utilized herein Pro-forms (also commonly referred to as pro-drugs) are those forms which, upon hydrolysis in vivo, provide the free L-arginine. Non-limiting, but preferred, examples of such pro-forms include amides of L-arginine, particularly amides of the .alpha.-nitrogen of L-arginine. For example, methyl, ethyl, propyl, and butyl amides are preferred pro-forms herein.

As described further herein, the L-arginine is actually an ester of a moiety designated herein as "R" which is a glycerol backbone, a substituted glycerol backbone, a vitamin, a sterol, a stanol, C.sub.6 - C.sub.32 alkyl, or C.sub.6 -C.sub.32 alkenyl. As will be further described, in some instances, more than

one molecule of L-arginine (or salt, polypeptide, or pro-form) may be attached to the substituted glycerol backbone. The R moieties are further described below.

### Substituted Glycerols

The compound of the present invention may be an ester of a substituted glycerol backbone (described herein for simplicity as substituted glycerol) and L-arginine, or acceptable salts, polypeptides, and pro-forms thereof. The compound may be either mono-substituted or di-substituted with a moiety other than L-arginine or the normally occurring hydroxyl moiety. Thus, wherein the compound is mono-substituted, two L-arginine molecules are esterified and n is 2, or one L-arginine molecule is esterified and one free hydroxyl moiety is present on the substituted glycerol. Similarly, wherein the compound is di-substituted, one L-arginine molecule is esterified and n is 1. Preferably, wherein R is a substituted glycerol, the substituted glycerol is di-substituted.

As used herein, the term "substituted" means that one or more hydroxy moieties on the glycerol backbone is substituted with a moiety independently selected from alkyl, alkenyl, acylalkyl, and acylalkenyl. Preferably, one or more hydroxy moieties on the glycerol backbone are substituted with a moiety independently selected from acylalkyl and acylalkenyl, most preferably acylalkenyl. Such alkyl, alkenyl, acylalkyl, or acylalkenyl may be further substituted with a substituent selected from alkyl, alkenyl, alkoxy (i.e., --O-alkyl or --O-alkenyl), hydroxy, oxo (C(O)), nitro, amino, cyano, halo, carboxy, acylalkyl, acylalkenyl, thiol, imino, thioxo (C(S)), preferably alkyl, alkoxy, hydroxy, oxo, nitro, amino, halo, and thiol, more preferably alkyl, alkoxy, hydroxy, oxo, nitro, amino, and halo, even more preferably alkyl, alkenyl, and alkoxy.

For example, the substituted glycerol may be a di-substituted glycerol (n is 1) wherein two hydroxy moieties of the glycerol backbone are independently substituted with an acylalkyl. To illustrate, such compound has the structure: ##STR5##

wherein R.sub.1 and R.sub.2 are each, independently, alkyl.

Wherein the glycerol backbone is substituted with a moiety selected from acylalkyls and acylalkenyls, it is preferred that such moieties are derived from readily available fatty acids, preferably those which are suitable for use in food and beverage compositions. Such fatty acids include, but are not limited to, C.sub.6 fatty acid, C.sub.8 fatty acid, C.sub.10 fatty acid, C.sub.12 fatty acid (e.g., laurate), C.sub.14 fatty acid (e.g., myristate), C.sub.16 fatty acid (e.g., palmitate and palmitoleate), C.sub.18 fatty acid (e.g., stearate, oleate, linoleate, and linolenate), C.sub.20 fatty acid (e.g., arachidate and arachidonate), C.sub.22 fatty acid (e.g., behenate), and C.sub.24 fatty acid (e.g., lignocerate).

In a particularly preferred embodiment, one or two (preferably, two) hydroxy moieties on the glycerol backbone are independently substituted with an acylalkenyl moiety, such as one derived from the above fatty acids and having at least one olefinic bond. Preferred acylalkenyls are those which are derived from .quadrature.-3-fatty acids. As is known in the art, .quadrature.-3-fatty acids are those fatty acids which have an olefinic bond bridging carbon atoms 3 and 4, wherein the carbon atoms of the fatty acid chain are counted from the .quadrature. (distal) end of the fatty acid. Therefore, as used herein, a particularly preferred embodiment is wherein one or more hydroxy moieties on the glycerol backbone are substituted with an .quadrature.-3-acylalkenyl. To illustrate, such compounds may have the following non-limiting structure: ##STR6##

wherein R.sub.1 and R.sub.2 are each, --CH.sub.2 --; and wherein x and x' are independent integers typically from about 3 to about 33. Alternatively, as another non-limiting example, the .quadrature.-3-fatty acid chains may comprise one or more additional olefinic bonds.

## Vitamins

The compounds of the present invention may also be an ester of a vitamin and L-arginine, or salts, pre-forms, or polypeptides thereof. In this embodiment of the present invention, the integer n will be 1. Preferably, the vitamin utilized bears at least one hydroxy moiety, making the vitamin readily available for esterification.

Utilization of a vitamin herein provides not only reduction or removal of unacceptable flavor of the L-arginine, but also provides an additional nutritional benefit imparted by such vitamin. Since ingestion and absorption of the present compounds will result in in vivo hydrolysis of the ester functionality, the vitamin utilized will be released, providing the nutritional benefit of such vitamin. Nutritional benefits of the various vitamins are well-known in the art. Accordingly, utilization of a vitamin for the R moiety of the present ester compounds is a particularly preferred embodiment of the present invention.

The vitamin utilized herein should be one which comprises a hydroxy moiety, thus making such vitamin suitable for esterification with L-arginine. Non-limiting examples of such vitamins include vitamin A, vitamin D, vitamin E, and vitamin K.sub.5. Additionally, the present inventors have discovered that the fat-soluble vitamins, e.g., vitamin A, vitamin D, and vitamin E, are most preferred herein due to their lipophilicity. As discovered herein, wherein the L-arginine is made more lipophilic, the adverse flavor of the L-arginine is diminished and/or removed more readily. Accordingly, while any vitamin bearing a hydroxy moiety may be utilized, it is preferred that R is selected from vitamin A, vitamin D, and vitamin E. The most preferred vitamin for use as R is vitamin E.

As used herein, all forms of these vitamins are contemplated for use. For example, vitamin D can include vitamin D.sub.1, D.sub.2, D.sub.3, and D.sub.4. Similarly, vitamin A can include vitamin A and A.sub.2. Preferably, wherein vitamin A is used, such vitamin A is in the form of retinol. Also preferably, wherein vitamin E is utilized, such vitamin E is a tocopherol (e.g., .alpha.-tocopherol, .beta.-tocopherol, .gamma.-tocopherol, and .delta.-tocopherol, preferably .alpha.-tocopherol) or a tocotrienol (e.g., .alpha.-tocotrienol, .beta.-tocotrienol, .gamma.-tocotrienol, and .delta.-tocotrienol. Most preferably, such vitamin E is .alpha.-tocopherol.

Non-limiting examples of preferred compounds wherein R is a vitamin are set forth in Table 1 below. If desired, these compounds may be modified as their acceptable salts, polypeptides, and pro-forms.

TABLE 1 Non-limiting Examples of Compounds Wherein R is a Vitamin R Compound Vitamin A  
##STR7## Vitamin A.sub.2 ##STR8## Vitamin D.sub.2 ##STR9## Vitamin D.sub.3 ##STR10##  
Vitamin D.sub.4 ##STR11## Vitamin E ##STR12##

## Sterols

The compound of the present invention may also be an ester of L-arginine and a sterol. In this embodiment of the present invention, the integer n will be 1.

Utilization of a sterol herein provides not only reduction or removal of unacceptable flavor of the L-arginine, but also provides an additional cardiovascular benefit imparted by such sterol. Since ingestion and absorption of the present compounds will result in in vivo hydrolysis of the ester functionality, the sterol utilized will be released, providing the cardiovascular benefit of such sterol. As has recently been discovered, sterols may be utilized in food compositions to enhance cardiovascular health, for example, by decreasing serum cholesterol levels. Accordingly, use of such sterols surprisingly improves the flavor of L-arginine, while providing additional health benefits to the consumer.

Sterols which are useful herein are commonly known in the art. As non-limiting examples, such sterols are described in Stern, U.S. Pat. No. 3,004,043, assigned to Eastman Kodak Co., issued Oct. 10, 1961; Wruble et al., U.S. Pat. No. 3,085,939, issued Apr. 1, 1963; Erickson, U.S. Pat. No. 3,751,569, assigned to The Procter & Gamble Co., issued Aug. 7, 1973; Jandacek, U.S. Pat. No. 3,865,939, assigned to The Procter & Gamble Co., issued Feb. 11, 1975; Ong, U.S. Pat. No. 4,195,084, assigned to Eli Lilly and Co., issued Mar. 25, 1980; Malinow, U.S. Pat. No. 4,461,762, assigned to Medical Research Foundation, issued Jul. 24, 1984; Arichi et al., U.S. Pat. No. 4,524,067, assigned to Osaka Chemical Lab. Co., issued Jun. 18, 1985; Malinow, U.S. Pat. No. 4,602,003, assigned to Medical Research Foundation, issued Jul. 22, 1986; Cassal, U.S. Pat. No. 4,680,290, assigned to Hoffman-La Roche Inc., issued Jul. 14, 1987; Ambrus et al., U.S. Pat. No. 5,112,815, issued May 12, 1992; Straub, U.S. Pat. No. 5,244,887, issued Sep. 14, 1993; Eugster et al., U.S. Pat. No. 5,270,041, assigned to Marigen S. A., issued Dec. 14, 1993; Mazur et al., U.S. Pat. No. 5,591,836, assigned to The Procter & Gamble Co., issued Jan. 7, 1997; Moreau et al., U.S. Pat. No. 5,843,499, assigned to United States of America, issued Dec. 1, 1998; Miettinen et al., U.S. Pat. No. 5,958,913, assigned to Raisio Benecol Ltd., issued Sep. 28, 1999; Karppanen et al., WO 98/28990, assigned to Pharmaconsult, published Jul. 9, 1998; Shirakawa et al., EP 0,289,636, published Nov. 9, 1988; Ko, WO 94/18225, assigned to Du Pont Merck Pharmaceutical, published Aug. 18, 1994; Festo, WO 95/08342, assigned to Inpharma S. A., published Mar. 30, 1995; Ritter et al., WO 97/42830, assigned to Unilever PLC, published Nov. 20, 1997; Van Amerongen et al., WO 98/01126, assigned to Unilever PLC, published Jan. 15, 1998; and Wester et al., WO 98/06405, assigned to Raisio Tehtaat, published Feb. 19, 1998. Any of the sterols described in the foregoing references, as well as those commonly known in the art, may be utilized for the R moiety of the present compounds.

Thus, the term "sterol" as used herein can include natural or synthetic plant or animal sterols or triterpenes. This includes the phytosterols and the mycosterols as well as cholesterol, however it is preferred herein that cholesterol itself is not utilized. For a more detailed discussion of sterols see, for example, Nes, W. D., Parish, E. J., Eds., "Analysis of Sterols and Other Biologically Significant Steroids", Academic Press, Inc. (1989). Non-limiting examples of preferred sterols include diosgenin, stigmasterol, tigogenin, .quadrature.-sitosterol, .quadrature.-sitosterol, stigmasterol, ergosterol, campesterol, oleanoic acids, soyasapogenols, protoascigenin, togenols, protopanaxadiols, protopanaxadiols, .quadrature.-amyirin, .quadrature.-amyirin, lupeol, butyrospermol, germanicol, 4-desmethylsterols, 4-monomethylsterols, and 4,4'-dimethylsterols. Other non-limiting examples of sterols for use herein include 7-dehydrocholesterol, 22-dehydrocholesterol, 24-dehydrocholesterol, zymosterol, .DELTA..sup.7 -cholesterol, cerebrosterol, 22-.alpha.-oxycholesterol, 22-dihydroergosterol, neospongosterol, cerebisterol, corbisterol, focosterol, .alpha.-spinasterol, sargasterol, 7-dehydrocrynasterol, poriferasterol, chondrillasterol, cryonasterol (.gamma.-sitosterol), dihydro-.gamma.-sitosterol, 14-dehydroergosterol, 24(28)-dehydroergosterol, ergosterol, brassicasterol, 24-methylenecholesterol, ascosterol, episterol, fecosterol, and 5-dihydroergosterol.

It is particularly preferred herein that phytosterols are utilized herein. The term phytosterol is intended to mean unsaturated sterol alcohols and their mixtures derived from plants, as well as synthetically produced sterol alcohols and their mixtures which are either identical to those sterols found in nature, or having properties which are similar to those of naturally occurring sterols. As is well-known in the art, phytosterols (also commonly referred to as plant sterols) are, natural components of, for example, vegetable fats and oils.

The most preferred phytosterols for use as the R moiety herein include sitosterols (e.g., .beta.-sitosterol (24-ethyl-5-.alpha.-cholestane-3.beta.-ol and 5.alpha.-sitosterols), stigmasterol, and campesterol. Schematic drawings of these components are as given in S. P. Kochhar, "Influence of Processing on Sterols of Edible Vegetable Oils", Prog. Lipid Res., Vol. 22, pp. 161-188. For example, .beta.-sitosterol

has the following structure: ##STR13##

Accordingly, as a non-limiting example, where R is .beta.-sitosterol, a compound of the present invention has the structure: ##STR14##

Preparation of phytosterols is commonly known; for example, sitosterol can be obtained from wood and from refining vegetable oil, and normally comprises a minor amount of other sterols, such as campesterol, stigmasterol, and various avenasterols. Other suitable phytosterols for use herein include brassicasterol and 22,23-dihydrobrassicasterol.

### Stanols

The compound of the present invention may also be an ester of L-arginine and a stanol. In this embodiment of the present invention, the integer n will be 1.

As with utilization of a sterol, the stanol herein provides not only reduction or removal of unacceptable flavor of the L-arginine, but also provides an additional cardiovascular benefit imparted by such stanol. The stanol utilized will be released upon in vivo hydrolysis, providing the cardiovascular benefit of such stanol. As has recently been discovered, stanols may be utilized in food compositions to enhance cardiovascular health, for example, by decreasing serum cholesterol levels. Accordingly, use of such stanols surprisingly improves the flavor of L-arginine, while providing additional health benefits to the consumer.

Stanols are found in small amounts in nature in such products as wheat, rye, corn, and tritcale. They can also easily be produced by hydrogenation of natural sterol mixtures such as vegetable oil-based sterol mixtures or commercially available wood sterols. The plant sterols thus obtained can be converted into stanols by well-known hydrogenation techniques such as those based on the use of a Pd/C catalyst (or other similar catalyst) in organic solvent. A wide variety of palladium catalysts and solvents are known to those of ordinary skill in the art and such catalysis can be used to hydrogenate the sterol for formation of the desired stanol. For example, .beta.-sitostanol (24-ethyl-5.alpha.-cholestane-3.beta.-ol) may be prepared by hydrogenation of .beta.-sitosterol in organic solvent.

Accordingly, any sterol, including the foregoing examples of sterols, may be utilized to provide the desired stanol. Non-limiting examples of useful stanols therefore include the hydrogenation products of the sterols described herein. The most preferred stanols herein include stanols of the phytosterols, for example, sitostanols (e.g., .beta.-sitostanol and 5.alpha.-sitostanols), campestanol, 24-.beta.-methylcholestanol, stiginastanol, clionastanol, and dihydrobrassicastanol, which may be described herein as phytostanols. For example, four major phytostanols are campestanol, 22,23-dihydrobrassicastanol, .beta.-sitostanol, and clionastanol, which have the following structure: ##STR15##

wherein X is --CH.sub.3 for campestanol and its epimer, 22,23-dihydrobrassicastanol and wherein X is -C.sub.2H.sub.5 for sitostanol and its epimer, clionastanol. Campestanol and 22,23-dihydrobrassicastanol differ only by their steric configuration at C.sub.24. Similarly, sitostanol and clionastanol differ only by their steric configuration at C.sub.24. Alternate nomenclature for clionastanol is (3.beta., 5.alpha., 24S)-stigmast-5an-3-ol; sitostanol is (3.beta., 5.alpha., 24R)-stigmast-5an-3-ol; campestanol is (3.beta., 5.alpha., 24R)-ergost-5an-3-ol; dihydrobrassicastanol is (3.beta., 5.alpha., 24S)-ergost-5an-3-ol.

Non-limiting examples of compounds which may be utilized herein and having R as a stanol therefore include those of the following structure: ##STR16##



wherein X is as described above for the major phytosterols.

#### C.sub.6 -C.sub.32 Alkyl and Alkenyl

The compounds suitable for use herein may also be esters of a C.sub.6 -C.sub.32 alkyl or C.sub.6 -C.sub.32 alkenyl and L-arginine, or salts, polypeptides, or pro-forms thereof. In this embodiment, the integer n will be 1.

It has been discovered that use of the present alkyls and alkenyls as esters of L-arginine significantly increases the lipophilicity of L-arginine which, in turn, surprisingly improves the flavor of L-arginine such that it is palatable and acceptable for use. Accordingly, compounds wherein the R moiety is C.sub.6 -C.sub.32 alkyl or C.sub.6 -C.sub.32 alkenyl are particularly preferred herein. Preferably, in this embodiment, R is C.sub.10 -C.sub.28 alkyl or alkenyl, more preferably C.sub.12 -C.sub.22 alkyl or alkenyl, and most preferably C.sub.16 -C.sub.22 alkyl or alkenyl.

Fatty alcohols may be utilized for esterification to provide the present ester compounds. For example, preferred alcohols include hexyl, octyl, decyl, lauryl, myristyl, cetyl, and stearyl alcohol. The most preferred alcohols for use herein are those which are suitable for use in foods and beverages.

Non-limiting examples of compounds wherein R is C.sub.6 -C.sub.32 alkyl are set forth below in Table 2.

TABLE 2 R Compound C.sub.6 alkyl ##STR17## C.sub.8 alkyl ##STR18## C.sub.10 alkyl ##STR19## C.sub.12 alkyl ##STR20## C.sub.14 alkyl ##STR21## C.sub.16 alkyl ##STR22## C.sub.18 alkyl ##STR23## C.sub.20 alkyl ##STR24## C.sub.22 alkyl ##STR25## C.sub.24 alkyl ##STR26## C.sub.26 alkyl ##STR27## C.sub.28 alkyl ##STR28## C.sub.30 alkyl ##STR29## C.sub.32 alkyl ##STR30##

Alkenyls of the compounds set forth in Table 2 are also particularly useful. For example, .omega.-3 alkenyls, i.e., those which have an olefinic bond between carbon atoms 3 and 4 of the .omega. (distal) end of the carbon chain are preferred embodiments herein. For example, wherein R is an .omega.-3 C.sub.8 alkenyl the corresponding L-arginine ester has the following structure: ##STR31##

#### Kits of the Present invention

The present invention further relates to kits comprising a compound as described herein, or a composition comprising such compound, and information that use of the compound/composition provides treatment against general health benefits. Such general health benefits include, but are not limited to, cardiovascular benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g. atherosclerosis, restenosis, thrombosis) and, for example, treating other cardiovascular conditions such as hypercholesterolemia, hypertension, poor circulation, and other complications associated with diabetes. Additionally, the kit may comprise information that use of the compound/composition provides an organoleptic benefit, for example acceptable (e.g., good) flavor.

The information provided within the kit may for example, be oral information disseminated as part of the kit, but is preferably written information. Such written information is typically present on packaging associated with the composition (e.g., a label present on a package containing the compound/composition or package insert included within the kit). As used herein, "written" means through words, pictures, symbols, and/or other visible information. Such information need not utilize the actual words but rather use of pictures, symbols, and the like conveying the same or similar meaning are contemplated within the scope of this invention. Such information may also include information about

general health benefits and reasons for which such health, and particularly treatment against certain disease states (including the aforementioned disease states), is important for the user.

### Methods of the Present Invention

The present invention also encompasses methods for providing certain health benefits, particularly, lowering serum cholesterol or treating other cardiovascular problems or diseases (as set forth herein) comprising systemically (generally, orally) administering to a mammal (preferably, a human) successive therapeutically effective doses of the present compositions. Such methods include treating, preventing, and/or inhibiting (collectively referred to herein as treating) one or more of the following: cardiovascular problems including, but not limited to, atherosclerosis, restenosis, thrombosis, hypercholesterolemia, hypertension, diabetes, vascular dysfunction, and poor circulation, and other problems such as shock. Preferred methods herein include treatment of one or more of atherosclerosis, hypercholesterolemia, hypertension, diabetes, and poor circulation.

In accordance with the methods of the present invention, a present compound or, preferably a composition comprising the compound, is administered to a mammal, preferably a human. Preferably such administration is oral. As used herein, the term "oral administration" (or the like) with respect to the mammal (preferably, human) means that the mammal ingests or is directed to ingest (preferably, for the purpose of treatment of one or more of the various health problems described herein) one or more compounds/compositions of the present invention. Wherein the mammal is directed to ingest one or more of the compounds/compositions, such direction may be that which instructs and/or informs the user that use of the composition may and/or will provide treatment for the particular health problem of concern. For example, such direction may be oral direction (e.g., through oral instruction from, for example, a physician, sales professional or organization, and/or radio or television media (i.e., advertisement) or written direction (e.g., through written direction from, for example, a physician or other medical professional (e.g., scripts), sales professional or organization (e.g., through, for example, marketing brochures, pamphlets, or other instructive paraphernalia), written media (e.g., internet, electronic mail, or other computer-related media), and/or packaging associated with the composition (e.g., a label present on a package containing the composition). As used herein, "written" means through words, pictures, symbols, and/or other visible descriptors.

Administration of the present compounds/compositions may be via any systemic method, however, such administration is preferably oral. Typically such administration is at least once monthly, but preferably weekly, and most preferably daily. Preferred dosages of the present compounds/compositions will vary. As one of ordinary skill will recognize such variations are largely dependent upon factors such as age, gender, weight, and health state of the consumer. However, it is often preferred that from about 0.05 grams to about 200 grams of the compound is administered daily either alone or in such composition. More preferably, from about 0.01 grams to about 20 grams, even more preferably from about 0.1 gram to about 45 grams, and most preferably from about 0.5 grams to about 27 grams of the compound is administered daily either alone or in such composition.

### Methods of Making

The compounds of the present invention are prepared according to methods which are well-known to those skilled in the art. The starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available as a starting material.

It is recognized that the ordinarily skilled artisan in the art of organic chemistry can readily carry out standard manipulations of organic compounds without further direction. Examples of such manipulations are discussed in standard texts such as J. March, Advanced Organic Chemistry, John

Wiley & Sons, 1992.

The skilled artisan will readily appreciate that certain reactions are best carried out when other functionalities are masked or protected in the compound, thus increasing the yield of the reaction and/or avoiding any undesirable side reactions. Often, the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many such manipulations can be found in, for example, T. Greene, *Protecting Groups in Organic Synthesis*, John Wiley & Sons, 1981.

The compounds of the present invention may have at least one chiral center (due to the use of L-arginine herein). As a result, one may selectively prepare one optical isomer, including diastereomers and enantiomers, over another, for example by chiral starting materials, catalysts or solvents, or may prepare both stereoisomers or both optical isomers, including diastereomers and enantiomers at once (a racemic mixture). Mixtures of optical isomers, including diastereomers, enantiomers, or stereoisomers may be separated using known methods, such as through the use of, for example, chiral salts and chiral chromatography.

As stated, the present compounds are made according to procedures which are well-known to the ordinarily skilled artisan. However, for convenience, as a general procedure, L-arginine and a second reactant (selected according to the desired final compound herein, for example, a sterol, vitamin, etc.), are combined along with an inert solvent system to facilitate the solubilization of both reactants. The reaction mixture is heated to a temperature below the decomposition temperature of the L-arginine. A base catalyst (along with a non-reactive emulsifier, if necessary) is added. The reaction is maintained under slight vacuum to remove any moisture generated during the reaction. Solvent is refluxed back into the reactor. Upon completion of the reaction, the reaction mixture is neutralized and the excess reactants are removed. The desired compound may be extracted and further purified using silica gel (or other chromatographic methods).

#### Use of the Present Compositions and Kits

The compounds described herein can be used in compositions comprising fat and non-fat components to provide general health benefits, including cardiovascular benefits, such as lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g., atherosclerosis, restenosis, thrombosis) and, for example, treating other conditions such as hypertension, poor circulation, and complications associated with diabetes. The compositions are useful in a wide variety of finished products, including pharmaceutical, food, and beverage products.

Preferred herein is use of the present compositions in food products, including those envisioned for use as a dietary supplement such as a health bar. In a preferred embodiment of the present invention, the compositions is in the form of a health bar.

As non-limiting examples, the compounds can be used in the production of baked goods in any form, such as mixes, shelf-stable baked goods (including health bars), and frozen baked goods. Applications include, but are not limited to, cakes, brownies, muffins, bar cookies, health bars, wafers, biscuits, pastries, pies, pie crusts, and cookies, including sandwich cookies and chocolate chip cookies, particularly the storage-stable dual-textured cookies described in Hong et al., U.S. Pat. No. 4,455,333. The baked goods can contain fruit, cream, or other fillings. Other baked good uses include breads and rolls, crackers, pretzels, pancakes, waffles, ice cream cones and cups, yeast-raised baked goods, pizzas and pizza crusts, baked farinaceous snack foods, and other baked salted snacks.

As stated, health bars are a particularly preferred embodiment of the present invention. The compounds can be incorporated into health bars, such as those described in Greenberg et al., U.S. Pat. No. 5,780,039. The foregoing doses of the present compounds may be included in the advantageous health bars according to the present invention.

In addition to their uses in baked goods, the compositions herein can be used alone or in combination with fats to make shortening and oil products. The fats can be synthetic or derived from animal or vegetable sources, or combinations of these. Shortening and oil products include, but are not limited to, shortenings, margarines, spreads, butter blends, lards, cooking and frying oils, salad oils, popcorn oils, salad dressings, mayonnaise, and other edible oil products. In a particular embodiment of the present invention, the compositions are selected from margarines, butter, dressings and spreads.

Other uses for the compositions of the present invention include partial or complete replacement fats and/or oils present in peanut butter, frozen desserts such as ice cream and ice cream coatings, whipped toppings, frosting products, processed meat products, including vegetable protein-based meat analog products, sauces, gravies, and dairy products such as milkshakes, milk products, coffee whiteners, and cheese products.

The compounds described herein are also particularly useful in beverage compositions. Such beverage compositions may be "near-water" beverages (slightly flavored water), milks, coffees, teas, colas, fortified beverages (e.g., calcium fortified beverage), and fruit juices.

Preferred beverage compositions of the present invention are those comprising a beverage member selected from the group consisting of water, fruit juice, tea solids, milk solids, fruit flavors, botanical flavors, and mixtures thereof. The beverage compositions herein are most preferably dilute juice beverages (particularly fruit juice beverages) and beverages containing tea solids, and beverage products comprising fruit juice and tea solids. Particularly preferred beverage products comprise both fruit juice and water. Other particularly preferred beverage products comprise both tea solids and water. In another preferred embodiment, "near water" (lightly flavored water) is utilized.

Various optional elements may be incorporated into the compositions and kits of the present invention. Non-limiting examples of optional elements are as follows:

#### Water

Water may be included in the compositions of the present invention, particularly wherein the compositions are beverage compositions. As used herein, the term "water" includes the total amount of water present in the composition. "Water" includes water from flavor agents, sugar syrups, and other sources, e.g., gum solutions. Water of hydration of, for example, calcium and other solids, is also included. Wherein water is included, water is preferably included at levels from about 0.1% to about 99.999%, more preferably from about 5% to about 99%, still more preferably from about 40% to about 95%, even more preferably from about 50% to about 90%, and most preferably from about 70% to about 90%, by weight of the composition.

#### Beverage Emulsions

Dilute juice beverages of the present invention may optionally, but preferably, comprise from about 0.2% to about 5%, preferably from about 0.5% to about 3%, and most preferably from about 0.8% to about 2%, of a beverage emulsion. This beverage emulsion can be either a cloud emulsion or a flavor emulsion.

For cloud emulsions, the clouding agent can comprise one or more fats or oils stabilized as an oil-in-water emulsion using a suitable food grade emulsifier. Any of a variety of fats or oils may be employed as the clouding agent, provided that the fat or oil is suitable for use in foods and/or beverages. Preferred are those fats and oils that have been refined, bleached and deodorized to remove off-flavors. Especially suitable for use as clouding agents are those fats that are organoleptically neutral. These include fats from the following sources: vegetable fats such as soybean, corn, safflower, sunflower, cottonseed, canola, and rapeseed; nut fats such as coconut, palm, and palm kernel; and synthetic fats. See e.g., Kupper et al., U.S. Pat. No. 4,705,691, issued Nov. 10, 1987, for suitable fat or oil clouding agents.

Any suitable food grade emulsifier can be used that can stabilize the fat or oil clouding agent as an oil-in-water emulsion. Suitable emulsifiers include gum acacia, modified food starches (e.g., alkenylsuccinate modified food starches), anionic polymers derived from cellulose (e.g., carboxymethylcellulose), gum ghatti, modified gum ghatti, xanthan gum, tragacanth gum, guar gum, locust bean gum, pectin, and mixtures thereof. See e.g., Kupper et al., U.S. Pat. No. 4,705,691, issued Nov. 10, 1987. Modified starches treated to contain hydrophobic as well as hydrophilic groups, such as those described in Caldwell et al., U.S. Pat. No. 2,661,349, are preferred emulsifiers for use as herein. Octenyl succinate (OCS) modified starches such as those described in Marotta et al., U.S. Pat. No. 3,455,838 and Barndt et al., U.S. Pat. No. 4,460,617 are especially preferred emulsifiers.

The clouding agent can be combined with a weighting agent to provide a beverage opacifier that imparts a total or partial opaque effect to the beverage without separating out and rising to the top. The beverage opacifier provides the appearance to the consumer of a juice-containing beverage. Any suitable weighting oil can be employed in the beverage opacifier. Typical weighting oils include brominated vegetable oil, glycerol ester of wood rosin (ester gum), sucrose acetate isobutyrate (SAIB) and other sucrose esters, gum damar, colophony, gum elemi, or others known to those skilled in the art. Other suitable weighting agents include brominated liquid polyol polyesters which are nondigestible. See e.g., Brand et al., U.S. Pat. No. 4,705,690, issued Nov. 10, 1987.

The cloud/opacifier emulsion is prepared by mixing the clouding agent with the weighting agent (for opacifier emulsions), the emulsifier and water. The emulsion typically contains from about 0.1% to about 25% clouding agent, from about 1% to about 20% weighting oil agent (in the case of opacifier emulsions), from about 1% to about 30% emulsifiers, and from about 25% to about 97.9% water (or quantum satis).

The particle size of the water-insoluble components of the emulsion is reduced by employing a suitable apparatus known in the art. Because the ability of emulsifying agents to hold oil in suspension is proportional to particle size, emulsions of particles with diameters of about 0.1 to about 3.0 microns are suitable. Preferably, the particles are about 2.0 microns or less in diameter. Most preferred is an emulsion in which substantially all the particles are 1.0 microns or less in diameter. The particle size is reduced by passing the mixture through an homogenizer, colloid mill or turbine-type agitator. Usually one or two passes is sufficient. See e.g., Kupper et al., U.S. Pat. No. 4,705,691, issued Nov. 10, 1987.

Flavor emulsions useful in beverage products of the present invention comprise one or more suitable flavor oils, extracts, oleoresins, essential oils and the like, known in the art for use as flavorants in beverages. This component can also comprise flavor concentrates such as those derived from concentration of natural products such as fruits. Terpeneless citrus oils and essences can also be used herein. Examples of suitable flavors include, for example, fruit flavors such as orange, lemon, lime and the like, cola flavors, tea flavors, coffee flavors, chocolate flavors, dairy flavors. These flavors can be derived from natural sources such as essential oils and extracts, or can be synthetically prepared. The flavor emulsion typically comprises a blend of various flavors and can be employed in the form of an emulsion, alcoholic extract, or spray dried. The flavor emulsion can also include clouding agents, with

or without weighting agents, as previously described. See e.g., Kupper et al., U.S. Pat. No. 4,705,691, issued Nov. 10, 1987.

Flavor emulsions are typically prepared in the same manner as cloud/opacifier emulsions by mixing one or more flavoring oils (from about 0.001% to about 20%) with an emulsifying agent (from about 1% to about 30%) and water. (The oil clouding agents can also be present). Emulsions of particles with diameters of from about 0.1 to about 3.0 microns are suitable. Preferably, the particles are about 2.0 microns or less in diameter. Most preferably, the particles are about 1.0 microns or less in diameter. The emulsifying agent coats the particularized flavor oil to aid in preventing coalescence and in maintaining an appropriate dispersion. The viscosity and specific gravity of the flavor emulsion are regulated to be compatible with the finished beverage. See e.g., Kupper et al., U.S. Pat. No. 4,705,691, issued Nov. 10, 1987.

### Flavor Agents

The compositions herein may optionally, but preferably, comprise one or more flavor agents. Preferably, such flavor agents are included in the beverage compositions and are typically selected from fruit juice, tea solids, milk solids, fruit flavors, botanical flavors, and mixtures thereof. Wherein fruit juice is included, the beverages of the present invention can comprise from about 0.1% to about 40%, preferably from about 1% to about 20%, more preferably from about 2% to about 10%, and most preferably from about 3% to about 6%, fruit juice. (As measured herein, the weight percentage of fruit juice is based on a single strength 2.degree. to 16.degree. Brix fruit juice). The fruit juice can be incorporated into the beverage as a puree, comminute, or as a single strength or concentrated juice. Especially preferred is incorporation of the fruit juice as a concentrate with a solids content (primarily as sugar solids) of from about 20.degree. to about 80.degree. Brix.

The fruit juice can be any citrus juice, non-citrus juice, or mixture thereof, which are known for use in dilute juice beverages. The juice can be derived from, for example, apple, cranberry, pear, peach, plum, apricot, nectarine, grape, cherry, currant, raspberry, gooseberry, elderberry, blackberry, blueberry, strawberry, lemon, lime, mandarin, orange, grapefruit, cupuacu, potato, tomato, lettuce, celery, spinach, cabbage, watercress, dandelion, rhubarb, carrot, beet, cucumber, pineapple, coconut, pomegranate, kiwi, mango, papaya, banana, watermelon, passion fruit, tangerine, and cantaloupe. Preferred juices are derived from apple, pear, lemon, lime, mandarin, grapefruit, cranberry, orange, strawberry, tangerine, grape, kiwi, pineapple, passion fruit, mango, guava, raspberry and cherry. Citrus juices, preferably grapefruit, orange, lemon, lime, and mandarin juices, as well as juices derived from mango, apple, passion fruit, and guava, as well as mixtures of these juices are most preferred.

Fruit flavors may also be utilized. As described above with respect to flavor emulsions, fruit flavors may be derived from natural sources such as essential oil and extracts, or can be synthetically prepared. Fruit flavors may be derived from fruits through processing, particularly concentrating. Wherein fruit juices are concentrated or evaporated, the water which is removed or the condensate contains volatile substances which comprise the flavor of the fruit. Often, such flavor is added to a juice concentrate to enhance the flavor thereof. The condensate may also be used to flavor "near waters" (lightly flavored water).

Botanical flavors may also be utilized. As used herein, the term "botanical flavor" refers to a flavor derived from parts of a plant other than the fruit; i.e., derived from nuts, bark, roots, and/or leaves. Also included within the term "botanical flavor" are synthetically prepared flavors made to simulate botanical flavors derived from natural sources. Botanical flavors can be derived from natural sources such as essential oils and extracts, or can be synthetically prepared. Suitable botanical flavors include jamaica, kola, marigold, chrysanthemum, chamomile, ginger, valerian, yohimbe, hops, eriodictyon, ginseng,

bilberry, rice, red wine, mango, peony, lemon balm, nut gall, oak chip, lavender, walnut, gentian, luoguo, cinnamon, angelica, aloe, agrimony, yarrow and mixtures thereof.

Tannic acid or other similar acids can be used to provide an astringent taste to the beverage. From about 0.001% to about 10% tannic acid is used. Other flavor enhancers, as well as flavorants such as chocolate and vanilla can also be used.

Wherein tea solids are included, the beverages of the present invention can comprise from about 0.01% to about 1.2%, preferably from about 0.05% to about 0.8%, by weight of the beverage product, of tea solids. The term "tea solids" as used herein means solids extracted from tea materials including those materials obtained from the genus *Camellia* including *C. sinensis* and *C. assamica*, for instance, freshly gathered tea leaves, fresh green tea leaves that are dried immediately after gathering, fresh green tea leaves that have been heat treated before drying to inactivate any enzymes present, unfermented tea, instant green tea, and partially fermented tea leaves. Green tea materials are tea leaves, tea plant stems, and other plant materials that are related and which have not undergone substantial fermentation to create black teas. Members of the genus *Phyllanthus*, *Catechu gambir* and *Uncaria* family of tea plants can also be used. Mixtures of unfermented and partially fermented teas can be used.

Tea solids for use in beverages of the present invention can be obtained by known and conventional tea solid extraction methods. A particularly preferred source of green tea solids can be obtained by the method described in Ekanayake et al., U.S. application Ser. No. 08/606,907, filed Feb. 26, 1996. Tea solids so obtained will typically comprise caffeine, theobromine, proteins, amino acids, minerals and carbohydrates. Suitable beverages containing tea solids can be formulated according to Tsai et al., U.S. Pat. No. 4,946,701, issued Aug. 7, 1990. See also, Ekanayake et al., U.S. Pat. No. 5,427,806, issued Jun. 26, 1995, for a suitable sources of green tea solids for use in the present invention.

Beverages according to the present invention may also comprise milk solids. These milk solids can be derived from various sources including whole milk, skim milk, condensed milk, and dried milk powder. As used herein, the term "milk" will be used to describe an aqueous dispersion of milk solids, such as fluid (whole or skim milk) or non-fat dry milk or condensed milk diluted with water. The amount of milk included typically ranges from about 5% to about 99.8%, preferably from about 5% to about 75%, more preferably from about 5% to about 40%, and most preferably from about 5% to about 15%. The amount of non-fat milk solids correlating to these levels of milk solids is in the range of from about 0.5% to about 8.2%, from about 0.5% to about 6.2%, from about 0.5% to about 3.3%, and from about 0.5% to 1.2% of the beverage, respectively.

#### Thickeners and Bulking Agents

Food and beverage compositions according to the present invention can further comprise one or more thickeners or bulking agents, including xanthan gum, carboxymethylcellulose, carboxyethylcellulose, hydroxypropylcellulose, methylcellulose, microcrystalline cellulose, starches, dextrans, fermented whey, tofu, maltodextrins, polyols, including sugar alcohols (e.g., sorbitol and mannitol), carbohydrates (e.g., lactose), propylene glycol alginate, gellan gum, guar gum, pectin, tragacanth gum, gum acacia, locust bean gum, gum arabic, gelatin, as well as mixtures of these thickeners. These thickeners and bulking agents are typically included in the compositions of the present invention at levels up to about 0.1%, depending on the particular thickener involved and the viscosity effects desired.

#### Sweeteners

The food and beverage compositions of the present invention can, and typically will, contain an effective amount of one or more sweeteners, including carbohydrate sweeteners and natural and/or

artificial no/low calorie sweeteners. The amount of the sweetener used in the compositions of the present invention typically depends upon the particular sweetener used and the sweetness intensity desired. For no/low calorie sweeteners, this amount varies depending upon the sweetness intensity of the particular sweetener.

The compositions of the present invention can be sweetened with any of the carbohydrate sweeteners, preferably monosaccharides and/or disaccharides. Sweetened compositions, particularly beverages, will typically comprise from about 0.1% to about 20%, most preferably from about 6 to about 14%, sweetener. These sweeteners can be incorporated into the compositions in solid or liquid form but are typically, and preferably, incorporated as a syrup, most preferably as a concentrated syrup such as high fructose corn syrup. For purposes of preparing beverages of the present invention, these sugar sweeteners can be provided to some extent by other components of the beverage such as, for example, the fruit juice component and/or flavors.

Preferred sugar sweeteners for use in compositions of the present invention are sucrose, fructose, glucose, and mixtures thereof. Fructose can be obtained or provided as liquid fructose, high fructose corn syrup, dry fructose or fructose syrup, but is preferably provided as high fructose corn syrup. High fructose corn syrup (HFCS) is commercially available as HFCS-42, HFCS-55 and HFCS-90, which comprise 42%, 55% and 90%, respectively, by weight of the sugar solids therein, as fructose. Other naturally occurring sweeteners or their purified extracts, such as glycyrrhizin, the protein sweetener thaumatin, the juice of Luo Han Guo disclosed in, for example, Fischer et al., U.S. Pat. No. 5,433,965, issued Jul. 18, 1995, and the like can also be used in the compositions of the present invention.

Suitable no/low calorie sweeteners include saccharin, cyclamates, L-aspartyl-L-phenylalanine lower alkyl ester sweeteners (e.g., aspartame); L-aspartyl-D-alanine amides disclosed in Brennan et al., U.S. Pat. No. 4,411,925; L-aspartyl-D-serine amides disclosed in Brennan et al., U.S. Pat. No. 4,399,163; L-aspartyl-L-1-hydroxymethylalkaneamide sweeteners disclosed in Brand, U.S. Pat. No. 4,338,346; L-aspartyl-1-hydroxyethylalkaneamide sweeteners disclosed in Rizzi, U.S. Pat. No. 4,423,029; L-aspartyl-D-phenylglycine ester and amide sweeteners disclosed in Janusz, European Patent Application 168,112, published Jan. 15, 1986; N-[N-3,3-dimethylbutyl]-L-.quadrature.-aspartyl]-L-phenylalanine 1-methyl ester sweeteners disclosed in Gerlat et al., WO 99/30576, assigned to The Nutrasweet Co., published Jun. 24, 1999; alltame, thaumatin; dihydrochalcones; cyclamates; steviosides; glycyrrhizins, synthetic alkoxy aromatics, such as Dulcin and P-4000; sucrolose; suosan; miraculin; monellin; sorbitol, xylitol; talin; cyclohexylsulfamates; substituted imidazolines; synthetic sulfamic acids such as acesulfame, acesulfame-K and n-substituted sulfamic acids; oximes such as perilartine; rebaudioside-A; peptides such as aspartyl malonates and succinilic acids; dipeptides; amino acid based sweeteners such as gem-diaminoalkanes, meta-aminobenzoic acid, L-aminodicarboxylic acid alkanes, and amides of certain alpha-aminodicarboxylic acids and gem-diamines; and 3-hydroxy-4-alkyloxyphenyl aliphatic carboxylates or heterocyclic aromatic carboxylates; and the like and mixtures thereof. A particularly preferred low calorie sweetener is aspartame.

#### Coloring Agent

Small amounts of coloring agents may be utilized in the compositions of the present invention. FD&C dyes (e.g., yellow #5, blue #2, red #40) and/or FD&C lakes are preferably used. By adding the lakes to the other powdered ingredients, all the particles, in particular the colored iron compound, are completely and uniformly colored and a uniformly colored composition is attained. Preferred lake dyes which may be used in the present invention are the FDA-approved Lake, such as Lake red #40, yellow #6, blue #1, and the like. Additionally, a mixture of FD&C dyes or a FD&C lake dye in combination with other conventional food and food colorants may be used. Riboflavin and .quadrature.-carotene may also be used. The exact amount of coloring agent used will vary, depending on the agents used and the intensity



desired in the finished product. The amount can be readily determined by one skilled in the art. Generally, if utilized, the coloring agent should be present at a level of from about 0.0001% to about 0.5%, preferably from about 0.001% to about 0.1%, and most preferably from about 0.004% to about 0.1%, by weight of the composition.

## Nutrients

The compositions herein (particularly the food and beverage compositions) can be fortified with one or more nutrients, especially one or more vitamins, minerals, and/or amino acids. The U.S. Recommended Daily Intake (USRDI) for vitamins and minerals are defined and set forth in the Recommended Daily Dietary Allowance-Food and Nutrition Board, National Academy of Sciences-National Research Council.

Any amino acid may be utilized herein, especially the naturally occurring amino acids. Preferred amino acids for inclusion herein are L-lysine and L-carnitine, particularly L-lysine.

Unless otherwise specified herein, wherein a given mineral is present in the product, the product comprises at least about 1%, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 40% to about 150%, and most preferably from about 60% to about 125% of the USRDI of such mineral. Unless otherwise specified herein, wherein a given vitamin is present in the product, the product comprises at least about 1%, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 20% to about 150%, and most preferably from about 25% to about 120% of the USRDI of such vitamin.

Non-limiting examples of such vitamins and minerals include iron, zinc, copper, calcium, phosphorous, niacin, thiamin, folic acid, pantothenic acid, iodine, vitamin A, vitamin C, vitamin B.sub.2, vitamin B.sub.3, vitamin B.sub.6, vitamin B.sub.12, vitamin D, vitamin E, and vitamin K. Preferably, wherein a vitamin or mineral is utilized the vitamin or mineral is selected from iron, zinc, calcium, niacin, thiamin, folic acid, iodine, vitamin A, vitamin C, vitamin B.sub.6, vitamin B.sub.12, vitamin D, and vitamin E. A particularly preferred mineral for use herein is calcium.

Commercially available vitamin A sources may also be included in the present compositions. Vitamin A can be provided, for example, as vitamin A palmitate (retinol palmitate) and/or as beta-carotene. The vitamin A may be in the form of, for example, an oil, beadlets or encapsulated. As used herein, "vitamin A" includes, but is not limited to, vitamin A, .beta.-carotene, retinol palmitate, and retinol acetate. Wherein vitamin A is present in the compositions herein, the product comprises at least about 1%, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 15% to about 150%, and most preferably from about 20% to about 120% of the USRDI of such vitamin. Wherein vitamin A is present in the products herein, it is especially preferred to include about 25% of the USRDI of vitamin A. The quantity of vitamin A to be added is dependent on processing conditions and the amount of vitamin A deliver desired after storage. Preferably, wherein vitamin A is included within the present compositions, the products comprise from about 0.0001% to about 0.2%, more preferably from about 0.0002% to about 0.12%, also preferably from about 0.0003% to about 0.1%, even more preferably from about 0.0005% to about 0.08%, and most preferably from about 0.001% to about 0.06% of vitamin A, by weight of the composition.

Commercially available sources of vitamin B.sub.2 (also known as riboflavin) may be utilized in the present compositions. Wherein vitamin B.sub.2 is present in the compositions herein, the product comprises at least about 1%, preferably at least about 5%, more preferably from about 5% to about 200%, even more preferably from about 10% to about 150%, and most preferably from about 10% to about 120% of the USRDI of such vitamin. Wherein vitamin B.sub.2 is present in the compositions

herein, it is especially preferred to include from about 15% to about 35% of the USRDI of vitamin B.sub.2.

Commercially available sources of vitamin C can be used herein. Encapsulated ascorbic acid and edible salts of ascorbic acid can also be used. Wherein vitamin C is present in the products herein, the product comprises at least about 1%, preferably at least about 5%, more preferably from about 10% to about 200%, even more preferably from about 20% to about 150%, and most preferably from about 25% to about 120% of the USRDI of such vitamin. Wherein vitamin C is present in the compositions herein, it is especially preferred to include about 100% of the USRDI of vitamin C. The quantity of vitamin C to be added is dependent on processing conditions and the amount of vitamin C deliver desired after storage. Preferably, wherein vitamin C is included within the present compositions, the compositions comprise from about 0.005% to about 0.2%, more preferably from about 0.01% to about 0.12%, also preferably from about 0.02% to about 0.1%, even more preferably from about 0.02% to about 0.08%, and most preferably from about 0.03% to about 0.06% of vitamin C, by weight of the composition.

Commercial sources of iodine, preferably as an encapsulated iodine may be utilized herein. Other sources of iodine include iodine-containing salts, e.g., sodium iodide, potassium iodide, potassium iodate, sodium iodate, or mixtures thereof. These salts may be encapsulated.

Nutritionally supplemental amounts of other vitamins which may be incorporated herein include, but are not limited to, vitamins B.sub.6 and B.sub.12, folic acid, niacin, pantothenic acid, folic acid, vitamin D, and vitamin E. Wherein the composition comprises one of these vitamins, the product preferably comprises at least 5%, preferably at least 25%, and most preferably at least 35% of the USRDI for such vitamin.

Minerals which may optionally be included in the composition herein are, for example, magnesium, zinc, iodine, iron, and copper. Any soluble salt of these minerals suitable for inclusion edible products can be used, for example, magnesium citrate, magnesium gluconate, magnesium sulfate, zinc chloride, zinc sulfate, potassium iodide, copper sulfate, copper gluconate, and copper citrate.

Calcium is a particularly preferred mineral for use in the present invention. Preferred sources of calcium include, for example, amino acid chelated calcium, calcium carbonate, calcium oxide, calcium hydroxide, calcium sulfate, calcium chloride, calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, calcium citrate, calcium malate, calcium titrate, calcium gluconate, calcium realate, calcium tantrate, and calcium lactate, and in particular calcium citrate-malate. The form of calcium citrate-malate is described in, e.g., Mehansho et al., U.S. Pat. No. 5,670,344, issued Sep. 23, 1997; Diehl et al., U.S. Pat. No. 5,612,026, issued Mar. 18, 1997; Andon et al., U.S. Pat. No. 5,571,441, issued Nov. 5, 1996; Meyer et al., U.S. Pat. No. 5,474,793, issued Dec. 12, 1995; Andon et al., U.S. Pat. No. 5,468,506, issued Nov. 21, 1995; Burkes et al., U.S. Pat. No. 5,445,837, issued Aug. 29, 1995; Dake et al., U.S. Pat. No. 5,424,082, issued Jun. 13, 1995; Burkes et al., U.S. Pat. No. 5,422,128, issued Jun. 6, 1995; Burkes et al., U.S. Pat. No. 5,401,524, issued Mar. 28, 1995; Zuniga et al., U.S. Pat. No. 5,389,387, issued Feb. 14, 1995; Jacobs, U.S. Pat. No. 5,314,919, issued May 24, 1994; Saltman et al., U.S. Pat. No. 5,232,709, issued Aug. 3, 1993; Camden et al., U.S. Pat. No. 5,225,221, issued Jul. 6, 1993; Fox et al., U.S. Pat. No. 5,215,769, issued Jun. 1, 1993; Fox et al., U.S. Pat. No. 5,186,965, issued Feb. 16, 1993; Saltman et al., U.S. Pat. No. 5,151,274, issued Sep. 29, 1992; Kochanowski, U.S. Pat. No. 5,128,374, issued Jul. 7, 1992; Mehansho et al., U.S. Pat. No. 5,118,513, issued Jun. 2, 1992; Andon et al., U.S. Pat. No. 5,108,761, issued Apr. 28, 1992; Mehansho et al., U.S. Pat. No. 4,994,283, issued Feb. 19, 1991; Nakel et al., U.S. Pat. No. 4,786,510, issued Nov. 22, 1988; and Nakel et al., U.S. Pat. No. 4,737,375, issued Apr. 12, 1988. Preferred compositions of the present invention will comprise from about 0.01% to about 0.5%, more preferably from about 0.03% to about 0.2%, even more preferably from about 0.05% to about 0.15%, and most preferably from about 0.1% to about 0.15% of calcium, by

weight of the composition.

Iron may also be utilized in the compositions of the present invention. Acceptable forms of iron are well-known in the art. The amount of iron compound incorporated into the composition will vary widely depending upon the level of supplementation desired in the final product and the targeted consumer. Iron fortified compositions of the present invention typically contain from about 5% to about 100%, preferably from about 15% to about 50%, and most preferably about 20% to about 40% of the USRDI for iron.

Ferrous iron is typically better utilized by the body than ferric iron. Highly bioavailable ferrous salts that can be used in the ingestible compositions of the present invention are ferrous sulfate, ferrous fumarate, ferrous succinate, ferrous gluconate, ferrous lactate, ferrous tartarate, ferrous citrate, ferrous amino acid chelates, as well as mixtures of these ferrous salts. While ferrous iron is typically more bioavailable, certain ferric salts can also provide highly bioavailable sources of iron. Highly bioavailable ferric salts that can be used in the food or beverage compositions of the present invention are ferric saccharate, ferric ammonium citrate, ferric citrate, ferric sulfate, as well as mixtures of these ferric salts. Combinations or mixtures of highly bioavailable ferrous and ferric salts can be used in these edible mixes and ready-to-serve beverages. The preferred sources of highly bioavailable iron are ferrous fumarate and ferrous amino acid chelates.

Ferrous amino acid chelates particularly suitable as highly bioavailable iron sources for use in the present invention are those having a ligand to metal ratio of at least 2:1. For example, suitable ferrous amino acid chelates having a ligand to metal mole ratio of two are those of formula:

where L is an alpha amino acid, dipeptide, tripeptide, or quadrapeptide ligand. Thus, L can be any ligand which is a naturally occurring alpha amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; or dipeptides, tripeptides, or quadrapeptides formed by any combination of these alpha amino acids. See e.g., Ashmead et al., U.S. Pat. No. 4,863,898, issued Sep. 5, 1989; Ashmead, U.S. Pat. No. 4,830,716, issued May 16, 1989; and Ashmead, U.S. Pat. No. 4,599,152, issued Jul. 8, 1986, all of which are incorporated by reference. Particularly preferred ferrous amino acid chelates are those where the reacting ligands are glycine, lysine, and leucine. Most preferred is the ferrous amino acid chelate sold under the mark Ferrochel.RTM. (Albion Laboratories, Salt Lake City, Utah) wherein the ligand is glycine.

In addition to these highly bioavailable ferrous and ferric salts, other sources of bioavailable iron can be included in the food and beverage compositions of the present invention. Other sources of iron particularly suitable for fortifying products of the present invention included certain iron-sugar-carboxylate complexes. In these iron-sugar-carboxylate complexes, the carboxylate provides the counterion for the ferrous (preferred) or ferric iron. The overall synthesis of these iron-sugar-carboxylate complexes involves the formation of a calcium-sugar moiety in aqueous media (for example, by reacting calcium hydroxide with a sugar, reacting the iron source (such as ferrous ammonium sulfate) with the calcium-sugar moiety in aqueous media to provide an iron-sugar moiety, and neutralizing the reaction system with a carboxylic acid (the "carboxylate counterion") to provide the desired iron-sugar-carboxylate complex. Sugars that can be used to prepare the calcium-sugar moiety include any of the ingestible saccharidic materials, and mixtures thereof, such as glucose, sucrose and fructose, mannose, galactose, lactose, maltose, and the like, with sucrose and fructose being the more preferred. The carboxylic acid providing the "carboxylate counterion" can be any ingestible carboxylic acid such as citric acid, malic acid tartaric acid, lactic acid, succinic acid, propionic acid, etc., as well as mixtures of these acids.

These iron-sugar-carboxylate complexes can be prepared in the manner described in, e.g., Nakel et al., U.S. Pat. Nos. 4,786,510 and 4,786,518, issued Nov. 22, 1988, both of which are incorporated by reference. These materials are referred to as "complexes", but they may exist in solution as complicated, highly hydrated, protected colloids; the term "complex" is used for the purpose of simplicity.

Zinc may also be utilized in the compositions of the present invention. Acceptable forms of zinc are well-known in the art. Zinc fortified products of the present invention typically contain from about 5% to about 100%, preferably from about 15% to about 50%, and most preferably about 25% to about 45% of the USRDI for zinc. The zinc compounds which can be used in the present invention can be in any of the commonly used forms such as, e.g., zinc sulfate, zinc chloride, zinc acetate, zinc gluconate, zinc ascorbate, zinc citrate, zinc aspartate, zinc picolinate, amino acid chelated zinc, and zinc oxide. Zinc gluconate and amino acid chelated zinc are particularly preferred.

### Carbonation Component

Carbon dioxide can be introduced into the water which is mixed with a beverage syrup or into the dilute beverage after dilution to achieve carbonation. The carbonated beverage can be placed into a container, such as a bottle or can, and then sealed. Any conventional carbonation methodology may be utilized to make carbonated beverage products of this invention. The amount of carbon dioxide introduced into the beverage will depend upon the particular flavor system utilized and the amount of carbonation desired.

### pH

The compositions of the present invention, particularly the beverage compositions, preferably have a pH of from about 2 to about 8, more preferably from about 2 to about 4.5, and most preferably from about 2.7 to about 4.2. Beverage acidity can be adjusted to and maintained within the requisite range by known and conventional methods, e.g., the use of food grade acid buffers. Typically, beverage acidity within the above recited ranges is a balance between maximum acidity for microbial inhibition and optimum acidity for the desired beverage flavor. Food compositions preferably have a pH of less than about 8.

### Non-Caloric or Reduced Calorie Fats

The compositions can be used in combination with non-caloric or reduced calorie fats, such as branched chain fatty acid triglycerides, triglycerol ethers, polycarboxylic acid esters, sucrose polyesters, sucrose polyethers, neopentyl alcohol esters, silicone oils/siloxanes, and dicarboxylic acid esters (particularly where the composition is a food composition). Other partial fat replacements useful in combination with the fat materials are medium chain triglycerides, highly esterified polyglycerol esters, acetin fats, polyoxyethylene esters, jojoba esters, mono/diglycerides of fatty acids, and mono/diglycerides of short-chain dibasic acids.

### Fiber Component

Similarly, food and beverage compositions can be made that combine the present compositions with dietary fibers to achieve the combined benefits of each. By "dietary fiber" is meant complex carbohydrates resistant to digestion by mammalian enzymes, such as the carbohydrates found in plant cell walls and seaweed, and those produced by microbial fermentation. Examples of these complex carbohydrates are brans, celluloses, hemicelluloses, pectins, gums and mucilages, seaweed extract, and biosynthetic gums. Sources of the cellulosic fiber include vegetables, fruits, seeds, cereals, and man-made fibers (for example, by bacterial synthesis). Commercial fibers such as purified plant cellulose, or

cellulose flour, can also be used. Naturally occurring fibers include fiber from whole citrus peel, citrus albedo, sugar beets, citrus pulp and vesicle solids, apples, apricots, and watermelon rinds.

These dietary fibers may be in a crude or purified form. The dietary fiber used may be of a single type (e.g., cellulose), a composite dietary fiber (e.g., citrus albedo fiber containing cellulose and pectin), or some combination of fibers (e.g., cellulose and a gum). The fibers can be processed by methods known to the art.

Primarily due to the present compositions, the foods and beverages herein can provide reduced serum cholesterol and thus reduced risk of heart disease. Additionally, the present compositions have acceptable organoleptic properties, particularly flavor and texture, despite the presence of L-arginine, polypeptides thereof, salts thereof, and pro-forms thereof.

Dietary foods can be made with the compositions to meet special dietary needs, for example, of persons who are obese, diabetic, or hypercholesterolemic. The present compositions can be a major part of a low-fat, low-calorie, low-cholesterol diet, or may supplement a normal diet, and they can be used alone or in combination with drug therapy, nutritional therapy, or other therapy. Combinations of food or beverage products made with the compositions can be used as part of a total dietary management regimen, based on one or more of these products, containing the compositions alone or in combination with one or more of the above-mentioned ingredients, to provide one or more of the above-mentioned benefits.

This discussion of the composition uses, combinations, and benefits, is not intended to be limiting or all-inclusive. It is contemplated that other similar uses and benefits can be found that will fall within the spirit and scope of this invention.

## EXAMPLES

The following examples are illustrative of uses of the present compositions. Such examples are non-limiting illustrations and various modifications thereof may be made by one of ordinary skill in the art with the benefit of the present disclosure.

### Example 1

A fat free health bar is prepared having the following composition:

Component Wt % Soy Protein Isolates 28 Fructose 25 High Fructose Corn Syrup 23.5 Raisins 6.8 Sterol Ester of L-arginine 10 Olean .TM. (sucrose polyester, commercially available from Procter & Gamble Co., Cincinnati, OH) Cinnamon 0.5 Salt 0.1 Sodium Bicarbonate 0.1

The Sterol ester of L-arginine and Olean.TM. are pre-mixed prior to blending with the remainder of the dry ingredients and formed into bars. Other dried fruits, for example, cranberries, apricots, and the like may be substituted for the raisins. The health bar is ingested once daily for a period of 12 weeks as a supplement to a normal diet. The health bar is shown to reduce serum cholesterol levels after this 12 week period.

### Example 2

A sports energy gel is prepared having the following composition:

Component Wt % Maltodextrin 54 Water 20 Fructose 12 Sterol Ester of L-arginine 10 Citric Acid 3

Vitamin C 0.5 Vitamin A 0.1 Artificial Flavor 0.2 Sodium Benzoate 0.1 Potassium Sorbate 0.1 All components are combined and heated for pasteurization.

### Example 3

A health shake suitable for use as a dietary supplement or meal replacement is prepared having the following composition:

Component Wt % Fat Free Milk 52.5 Vitamin E Ester of L-arginine 10 Water 18.5 Sugar 5 Fructose 5 Cocoa 3 Gum Arabic 2 Cellulose Gel 2 Canola Oil 1 Potassium Phosphate 0.3 Dextrose 0.3 Lecithin 0.1 Mono- and Diglycerides 0.1 Carrageenan 0.1 Vitamin and Mineral Mix 0.1 \*vitamin A, C, D, E, B-vitamins (B1, B2, B6, B12, Folate, and niacin), with minerals of iron and zinc


The finished composition can be canned or subjected to Ultra High Temperature (UHT) pasteurization by heating to 135-150.degree. C. for 5 seconds and then aseptically packaged to provide a ready-to-serve beverage.


### Example 4

A powder chocolate drink having the following composition is made by the process as described in Mehansho et al. U.S. Pat. Nos. 5,888,563 and 5,707,670. The di-substituted glycerol ester of L-arginine is co-mixed with the lecithin as described to reduce the negative flavor associated with L-arginine.

Component Wt % Sugar 55.5 Disubstituted glycerol ester of L-arginine 11.2 Non-fat dry milk 15 Sodium Chloride 0.43 Cocoa Powder (14% fat) 16.4 Colors 0.07 Butylated Hydroxytoluene (BHT) 0.1 Vitamin/Mineral Mix\* 0.55 Ferrous Fumarate 0.06 Artificial Chocolate Flavor 0.3 Lecithin 0.35 Stabilizer (cholesterol) 0.04 \*vitamin A, C, D, E, B-vitamins (B1, B2, B6, B12, Folate, and niacin), with minerals of iron and zinc

\* \* \* \* \*




[Simple Power Search](#) | [Business Search](#) | [Investment Search](#) | [Stock Quotes](#) | [Search News](#) | [GeoSearch](#)

## Nutrition Today

**Title:** Carrageenans: uses in food and other industries.

**Summary:** Carrageenans, also known as Irish Moss, are derived from the seaweed *crispus*. Until recently, they have been used in small amounts, in a limited number of foods, to alter taste, texture, or appearances.

Format  
for Print

Home

Help Center

Accounts

About

Alerts

Portfolio

**Source:** Nutrition Today  
**Date:** 11-12/1995  
**Price:** \$2.95  
**DocumentSize:** Long (8 to 25 pages)  
**DocumentID:** LW19970923040122988  
**Subject(s):** Carrageenin--Nutritional aspects; *Chondrus crispus*--Nutrit  
**CitationInformation:** (v30 n6) Start Page: p246(8) ISSN: 0029-666X  
**Author(s):** Huffman, Fatma G.  
 Shah, Zara C.  
**DocumentType:** Article

**MoneyBackGuarantee** If you buy an article and you are not satisfied with it, let us know and your money. Please press the "Money Back Guarantee" link for additional information about this product.

## Nutrition Today

### Carrageenans: uses in food and other industries.

Carrageenans, also known as Irish Moss, are derived from the seaweed *Chondrus crispus*. Until recently, they have been used in small amounts, in a limited number of foods, to alter taste, texture, or appearances. Evidence from animal studies indicates that they may be associated with both potentially adverse and beneficial physiological responses in segments of the population who may be ingesting higher amounts considerably in excess of the previous estimates of 2.5 grams.

Globally, *Chondrus crispus*, a marine species of Rhodophyta (red algae), is one of the most widely used edible seaweeds (Matsuhiro and Urzua, 1991), yet there are few consumers familiar with the natural appearance of the weed. In its chopped, dried, or composted form, the seaweed, a good supplemental source of protein, fiber, vitamins, and minerals (Holland et al., 1991), has been utilized by the agricultural industry in animal fodder and in fertilizers that improve the nutrient content as well as the mechanical properties of the soil (Lobban and Wynne, 1981). This in turn impacts on the nutrient content and quality of the resulting animal and plant products (Lobban and Wynne, 1981). The amount consumed directly by humans has little impact on nutritive intake.

Although human diets rarely include *C. crispus* in its natural form, in countries such as Ireland, this fresh seaweed is still collected from wild populations along the coastline and home-processed for use as a thickener in porridges, desserts, and other dishes (Lobban and Wynne, 1981). Caribbean consumers can purchase dried, packaged *C. crispus* that is used to prepare "Sea Moss," a thick milkshake-type drink (Nestle, 1990). In most industrialized countries, carrageenans extracted from *C.*

crispus are incorporated into food products (Matsuhiro and Urzua, 1991, Pintauro and Gilbert, 1990), so the consumer never comes into contact with the natural seaweed. Carrageenans, a term used interchangeably with *C. crispus* and Irish moss, encompass a group of sulfated polysaccharides that form gels and viscous liquids (Tong and Hicks, 1991). They have been popularized in the food industry because their performance is superior to the previously used alginates or the gelatins from animal sources (Guiry and Blunden, 1991). As emulsifiers, stabilizers, binders, and fat substitutes, carrageenans are used in food products such as ice cream, baby foods, processed and low-fat meat products, salad dressings, cheeses, and candies (Lobban and Wynne, 1981). Several other industries, such as the pharmaceutical/biomedical and cosmetic industries, also make use of the carrageenans extracted from *C. crispus* (Isaacs, 1990).

The pharmaceutical uses of carrageenans range from stabilizers, emulsifiers or colloids for suspensions, and gel coatings for pills, to bases for antacids, cough syrups, and ointments (Guiry and Blunden, 1991). Other areas of the biomedical industry use carrageenans as growth media in the production of antibiotics, or to hold bacteriostatic agents for ease of application (Mussenden et al., 1991).

The cosmetic industry, like the food and biomedical industries, depends heavily on carrageenans. Commonly used products such as soaps, shaving foams, and body lotions all contain carrageenans. These products capitalize on the dual ability of carrageenans to emulsify oil and water preparations yet allow them to be easily removed with water. Other products such as medicated creams, toothpastes and deodorants rely on the ability of carrageenans to hold bacteriostatic agents (Guiry and Blunden, 1991).

Some research has been done on the physiological effects of carrageenans in experimental animals. Researchers agree that many of the potential adverse effects, such as gastrointestinal tract ulceration (Nicklin and Miller, 1989) and depressed immunity (Baker et al., 1986) are dose-dependent. The beneficial effects of carrageenans, however, are not dose-dependent. Schlemmer (1989) discovered that under the simulated buffered conditions of the intestines, carrageenans did not bind minerals such as Ca, Zn, or Cu to the same extent as other dietary fibers.

In the study of heart disease, the effects of carrageenans on serum cholesterol and on intestinal mucinase activity have been studied. It was found that rats fed carrageenans at 5%, 10%, and 15% of the diet experienced approximately the same lowering effect on serum cholesterol. However, although the 5% carrageenan level decreased intestinal mucinase activity, the higher levels of carrageenans increased the activity of this enzyme (Shiau and Huang, 1987).

Most evidence suggests that only high levels of carrageenan intake can lead to nutritional risk. However, little research has been done to accurately estimate the average intake of Americans; nor has any attempt been made to investigate populations, such as dieters, the elderly, or infants who are likely to consume more than average amounts of carrageenan-containing products. The number of commonly used foods that contain carrageenans has grown almost exponentially since the late 1980s, when the average daily adult intake was estimated at 0 to 2.5 grams (Pintauro and Gilbert, 1990); however, this estimate neglected to take into account consumption of carrageenan-containing pharmaceutical products.

Carrageenan research carried out in the past generally involved blends of kappa, iota, and lambda carrageenans. Because these different types of carrageenans have slight variances in chemical structures and physical properties, it may be advantageous to observe the effects of the various types of carrageenan on gastrointestinal lining tissues, as well as to compare their impacts on serum



cholesterol and mineral bioavailability. It may also be useful to compare carrageenans with pectins, which are widely accepted as a beneficial soluble fiber for the same parameters.

Carrageenan, because of its soluble fiber properties, is incorporated widely into food and pharmaceutical products commonly ingested by humans. Yet little research has been done to compare carrageenans with other soluble fibers in terms of their physiological or other effects in animals.

Research in this area is particularly significant for populations such as infants who do not have fully developed gastrointestinal barriers in terms of permeability to pathogens and biologically active molecules. Because of the use of carrageenans to replace fats in foods dieters may consume sufficiently high proportions of this extract, to be susceptible to colitis or other damage to the gastrointestinal tract. The information gathered may be meaningful in planning the diets or establishing carrageenan intake limits for populations who are at risk of heart disease, gastrointestinal tract damage, and related immunosuppression. These populations include the elderly, infants, and individuals with HIV infection or diseases of the gastrointestinal tract and the immune system.

Carrageenans, increasingly are being incorporated into foods and pharmaceutical products in amounts ranging from 0% to 1.5% (Nicklin and Miller, 1989), and these carrageenan-containing products are gaining in popularity among both consumers and manufacturers because of their stability and convenience. However, not enough research has been done to truly guarantee the safety of these seaweed galactans, especially in view of research that has chronicled detrimental effects in experimental animals, even with small intakes of high quality (high molecular weight and viscosity) carrageenans.

Irish moss (*C. crispus*) is a red marine algae species (Fig. 1). In the wild, this temperature-sensitive seaweed is limited geographically to the cold regions of the North Atlantic Ocean, off the coast of Newfoundland, northern Norway, and New Jersey in the northern hemisphere, and Mauritania in the region of the African continent (Luning, 1990). In these areas, the water currents maintain the temperature around 17 [degrees] C (Luning, 1990). *C. crispus* appears to require a temperature of 15 [degrees] C to enter its sporophytic stage; photosynthesis ceases at 18 [degrees] C, and above 20 [degrees] C there is massive cell damage resulting in death (Guiry and Blunden, 1991).

*C. crispus*, like most red algae, has cell walls that appear to be layered and fibrillar under the electron microscope. The thickness and orientation of the layers vary from area to area within the same plant, largely dependent on the period for which the plant has been fixed in one location. The inner microfibrils (layers of the cell wall) are composed of cellulose, whereas the outer microfibrils and wall matrix are made of sulfated polysaccharides such as phycocolloids, mucilages, and the galactans known collectively as carrageenans. The term carrageenan is used interchangeably with Irish moss and *C. crispus*; however, technically, carrageenans are galactans that are primarily chains of beta-1,3 and alpha-1,4-linked galactose residues extracted from *C. crispus* (Chapman, 1979). Most of the approximately 300,000 tons, fresh weight, of *C. crispus* harvested globally per year is used for the extraction of carrageenan (Isaacs, 1992, Luning, 1990). The technology and uses pertaining to carrageenan have proliferated to such an extent that an industry devoted solely to the extraction of carrageenan has been created. Extracted algal polysaccharides is the form in which most people in industrialized nations, with the exception of Japan, utilize seaweed products. Therefore, the demand for carrageenan from industry has far exceeded the rate of harvesting and extraction of these galactans from cultivated and wild populations (Lobban and Wynne, 1981).

## THE CARRAGEENANS: BIOCHEMICAL COMPOSITION

The carrageenan content of *C. crispus* varies depending upon which of the two phases in its life history the seaweed is harvested (Matsuhiro and Urzua, 1991). During the gametophytic (plant exhibiting alternation of generations that bears sex organs) stage of the life cycle, *C. crispus* carrageenan is mainly (73%) composed of the kappa family of carrageenans. These form helices in the presence of ions such as calcium and sodium, and gel in aqueous solutions above pH 3.3 at temperatures below their melting points (Tong and Hicks, 1991). During the sporophytic stage (plant exhibiting alternation of generations that bears asexual spores), mainly the lambda family is found (Matsuhiro and Urzua, 1991). As with the kappa carrageenans, these differ only in the  $\alpha$ -Dgalactose residues (Bodeau-Bellion, 1983) and sulfation levels. The lambda carrageenans are viscous liquids which do not gel because they cannot form the helices that are characteristic of the kappa carrageenans (Tong and Hicks, 1991). The primary differences that influence the properties of kappa, iota, and lambda carrageenans are the number and position of the ester sulfate groups on the repeating galactose units (Fig. 2).

### COMMERCIAL UTILIZATION OF *C. CRISPUS*

There is evidence that dates back to 600 to 800 B.C., that the Chinese, Greeks, and Romans utilized various seaweeds in ways that gave rise to modern usage (Lobban and Wynne, 1981). *C. crispus* in recent years has been increasingly utilized in a myriad of ways by the agricultural and other industries (Lobban and Wynne, 1981).

The desirable structural and gelling properties of the carrageenans in *C. crispus* result in approximately 80% of the 15,500 metric tons of carrageenan produced globally per year being utilized in the food industry, and the remaining 20% is divided equally between the cosmetic and pharmaceutical industries (Guiry and Blunden, 1991). The specific, generally kappa, iota, and lambda carrageenans, that are commercially desirable exist within the immediate cell wall and the wall matrix (Chapman, 1979).

### ROLES IN THE AGRICULTURAL INDUSTRY

The agricultural industry uses *C. crispus* as animal fodder and as fertilizer. Its fiber, vitamin, and mineral content make it an excellent supplement to the regular animal diet. In coastal areas, after observing wild animals eating seaweed, farmers often allowed their animals to forage along the shoreline, especially when terrestrial fodder crops failed or were in short supply. This led to the commercial harvesting and processing of seaweed as a fodder supplement; later the by-products of seaweed processing were also utilized by other industries (Lobban and Wynne, 1981).

*C. crispus*, because of its nutritional composition, is chopped, liquified, composted, dried, or ashed for use as fertilizer by agronomists. It has a nitrogen content similar to that of regular barnyard manure and 3 times the level of potassium, but only one third the phosphorus content. In addition, the high organic matter content of the seaweed improves the mechanical and water retention properties of the soil. Fertilizers based on *C. crispus* contain small amounts of naturally occurring substances: auxin, cytokinin, and gibberellin that promote growth and ripening, as well as pathogen-inhibiting phenolic compounds. As an added bonus, these fertilizers are devoid of the fungi and weeds that often impair terrestrial plant growth. *C. crispus*, in its fertilizer and fodder roles, contributes greatly to the quantity, quality, and nutritional value of the animal and plant products of the agricultural industry (Lobban and Wynne, 1981).

### CARRAGEENANS IN THE FOOD INDUSTRY

Carrageenans: uses in food and other industries.

Unlike most edible seaweeds (eg wakame, kombu, kelp, and nori), which are eaten as vegetables in conjunction with other types of food, *C. crispus* is processed to extract its carrageenans, which in turn are used to alter the appearance, taste, texture, or flavor of other foods (Tong and Hicks, 1991). The nutrition composition of carrageenan is outlined in Table 1.

Table 1

Nutrient Content of *C. crispus*

Per 100g *C. crispus*

Proximated composition (components)

Edible portion (g)	1.00
Water (g)	81.3
Nitrogen (g)	0.24
Protein (g)	7.1
Fat (g)	1.6
Carbohydrate (g)	tr
Energy (kcal)	8

Carbohydrate fractions (nutrients, in g)

Starch	0
Total sugars	tr
Glucose	tr
Fructose	tr
Sucrose	tr
Maltose	0
Lactose	0
Total dietary fiber	12.3
Cellulose	0
Soluble noncellulosic fiber	12.3
Insoluble noncellulosic fiber	0
Lignin	0

## Vitamin and mineral content

## Vitamin

Vitamin C (mg)	n/a
Retinol ([micro]g)	0.0
Carotene ([micro]g)	n/a
Vitamin D ([micro]g)	0.0
Vitamin E ([micro]g)	n/a
Thiamin (mg)	0.01
Riboflavin (mg)	0.47
Niacin (mg)	0.6
Vitamin [B.sub.6] (mg)	n/a
Vitamin [B.sub.12] ([micro]g)	tr
Folate ([micro]g)	n/a
Pantothenate (mg)	0.18
Biotin ([micro]g)	n/a

## Mineral

Sodium (mg)	67
Potassium (mg)	63
Calcium (mg)	72
Magnesium (mg)	n/a
Phosphorus (mg)	160
Iron (mg)	8.9
Copper (mg)	0.15
Zinc (mg)	1.0
Sulfur (mg)	n/a
Chlorine (mg)	n/a

Manganese (mg)	0.4
Selenium ([micro]g)	n/a
Iodine ([micro]g)	n/a

From Holland et al., 1990

The dairy industry has extensively used kappa carrageenans to enhance a variety of products, from cheeses (Kailasapathy et al., 1992) to desserts (Descamps et al., 1986), and even infant formulas (Pintauro and Gilbert, 1990). The carrageenans with the ability to gel have been used to improve the texture of cottage cheese. Further, carrageenans were found to bind casein micelles; thus, more of the milk proteins previously lost in the whey during cheese production were captured by the carrageenan. The yield and protein-content of the cheeses were greatly increased. At 1000 ppm, kappa and iota carrageenan increased cottage cheese curd yield by approximately 15% to 20%, respectively. The bitterness that results from calcium fortification of cottage cheese by the addition of calcium salts such as lactates and citrates, appears to be masked when 10% to 30% of the cheese is replaced with a 1.5% carrageenan solution. Other carrageenans in the lambda family, because of their ability to provide firmness without gelling, are used in low-fat cheeses to mimic the textural aspects of high-fat cheeses (Brummel and Lee, 1990). In dairy desserts and puddings, carrageenans are used in conjunction with low levels of starch to control the viscosity and texture of the final products after they have been subjected to the ultra-high temperatures required during processing. The carrageenans diminish syneresis, which frequently occurs in manufactured products containing starches, making them undesirable. In addition, when carrageenans are used in conjunction with starches, lower proportions of the starches are required to produce the desired texture, and thus the final product has fewer calories (Descamps et al., 1986). In the manufacture of flavored milk drinks (eg chocolate, strawberry), carrageenans are used as a stabilizer which prevents the separation and settling of the flavoring agents (Lobban and Wynne, 1981).

Use of carrageenans as binders and stabilizers has also escalated in the meat-processing industry, for fish, poultry, and meat products such as patties and sausages (Lobban and Wynne, 1981). The increasing consumer demand for low-fat meat products has prompted the development of low-fat hamburgers such as the McLean Deluxe marketed by the McDonald's Corporation. Iota carrageenan freezes and thaws well, which makes it even more valuable to the low-fat meat products industry (Egbert et al., 1991).

Lambda carrageenans have been used as an alternative to the previously used sulfites, which are potentially harmful to asthmatics, to prevent enzymatic browning through oxidation of polyphenols in cut, uncooked, or unblanched fruits and vegetables or juices (Tong and Hicks, 1991). Neither lambda carrageenan nor citric acid alone prevents browning; however when used together they inhibit browning for up to 7 days. The viscous lambda carrageenans are also thought to form a thin coating over the fruit and vegetables, thereby preventing nonenzymatic browning, the Maillard reaction between sugars, amines, amino acids, peptides, or proteins (Tong and Hicks, 1991).

In general, carrageenans have been used for a myriad of reasons, in a multitude of food products. A selective listing is provided in Table 2.

Table 2

## Food Products Containing C.

Crispus or carrageenans

### Dairy Foods

Ice Creams/Ice milks

Low fat cheeses

Whipped toppings

Cake and pie fillings/glazes

Yogurt

Puddings

Flavored milks

### Other Foods

Low-calorie jams and jellies

Instant breakfast drinks

Salad dressings

Candies

Low-fat processed meats--sausages,

lunchmeats, etc.

Browning inhibitors (fresh

fruit/vegetable/juice processing)

Carrageenan leaves (for home use as a

thickener, etc.)

## CARRAGEENANS IN THE COSMETICS INDUSTRY

The ability of carrageenans to absorb and relinquish high proportions of water is perhaps one of the most significant reasons for their use in the cosmetic industry. In sunscreens, carrageenans provide a stable gel base for screening agents, and as the water in the gel evaporates, there is the bonus of a pleasant, cooling sensation, and only a thin film of screening agents is left on the skin. Carrageenans, ability to emulsify and stabilize oil and water mixtures promotes their use in products such as creams, lotions, soaps, facial masks, and shaving foams that can be easily removed by rinsing with water. Easy removal with water also makes carrageenans ideal for use in hair-styling products.

In antiseptic products such as antigingivitis toothpastes and medicated antiacne creams, carrageenan gels have replaced the formerly used alginates because of their superior stability and ability to hold bacteriostatic agents. In deodorants, these bacteriostatic agents inhibit the growth of the bacteria causing an offensive odor (Guiry and Blunden, 1991).

## CARRAGEENAN IN THE PHARMACEUTICAL INDUSTRY

The list of uses of *C. crispus* in the pharmaceutical industry is truly extensive, with the seaweed having long been used in cough syrups, lozenges, and in soothing treatments for chest and stomach ailments (Lobban and Wynne, 1981). However, the carrageenans and other extracts of *C. Crispus* are used in the pharmaceutical industry, which focuses on the thickening, emulsifying, and stabilizing abilities of carrageenans in relation to oil-in-water preparations. Nevertheless, other uses are found for the non-helix-forming carrageenans in soluble aspirin or for coatings that encase pills and capsules for ease in swallowing (Gordon-Mills, 1990).

More recent experimental uses of *C. crispus* center on the antipathogenic extracts of the seaweed. In the late 1970s, researchers speculated on the possible antibacterial/antiviral functions of the newly discovered seaweed extracts, Kainic and Domoic acids (Lobban and Wynne, 1981). Later research showed that the youngest tissues in new *C. crispus* growth produced these phenolic acids as a defense against bacterial and fungal attack (Lobban et al., 1985).

In addition to the previous pharmaceutical uses, kappa carrageenan beads have been used as a growth medium for the aerobic microorganism *Penicillium chrysogenum*, a major source of penicillin (Mussenden et al., 1991). The *P. chrysogenum* requires a medium that can provide a large enough surface area, moisture, and adequate access to oxygen to support rapid growth (Mussenden et al., 1991).

## REGULATIONS AND PROCEDURES REGARDING EXTRACTION

Because *C. crispus* and its carrageenan and other extracts are ingredients in so many of a variety of commonly used products throughout the world, it is of great concern to manufacturers and consumers that the raw seaweed be relatively free of harmful contaminants and toxins. Although wild populations of the seaweed are likely to be adulterated, especially where they are exposed to hospital or sewer effluents or industrial pollution, globally regulated and accepted processing generally removes impurities (Gordon-Mills, 1990; Nicklin and Miller, 1989).

Standardization and monitoring of processing are perhaps the only means of ensuring the safety and quality of seaweed derivatives that are incorporated into manufactured products (Anderson, 1992). The poorest quality of carrageenans are those referred to as "degraded", and these are the lowmolecular-weight (approximately 20,000), low-viscosity products of acid hydrolysis of native (a mixture of kappa, lambda, and iota) carrageenans (Baker et al., 1986). In several experimental animals, degraded carrageenans have produced ulceration of the gastrointestinal tract (Baker et al., 1986). In general, carrageenans are marketed as blends of the kappa, lambda, and iota forms (approximate y 500,000 molecular weight) that conform to specified minimum viscosity levels (Anderson, 1992). These regulations, however, have proved inadequate, in that some unscrupulous manufacturers blend enough high-quality, high-viscosity carrageenans with the poorquality, low-viscosity, degraded form, to meet specifications. Most of the global producers of carrageenans belong to an alliance that funds toxicological studies and testing, and they follow strict specifications regarding extraction procedures. Recently, however, regardless of protests by other world nations, the

government of the Phillipines successfully lobbied to have their seaweed derivatives approved by the U.S. Food and Drug Administration, despite their neglect of the alcoholic precipitation step for removal of soluble contaminant residues in their extraction procedures. The Filipino extraction process is cheaper and faster because there are fewer steps, meaning that their products can be sold cheaper and faster. No toxicological analyses were performed on the Filipino products before FDA approval, and outwardly there are no distinguishable differences between the products of the Phillipines and other world seaweed processors. Members of the global alliance of seaweed processors fear that any adverse reactions that occur from the use of the Filipino products may be associated with their products (Anderson, 1992).

## THE EFFECTS OF DIETARY CARRAGEENANS

The wide usage of carrageenans in the food industry generates some concern over its potential negative effects on the nutritional and physiological health in man (Nicklin and Miller, 1989). The dairy and diet industries have capitalized on the characteristics of the carrageenans that allow them to alter texture, flavor, fat and caloric content of foods (Descamps, 1986), and to suspend proteins (Nicklin and Miller, 1989).

As carrageenans gain in popularity as food and pharmaceutical additives, they are incorporated into more products, and normal daily intakes especially for infants and dieters may increase far in excess of the levels currently estimated at up to 2.5 grams. Immunological disorders (Nicklin and Miller, 1989), as well as gastrointestinal ulceration (Baker et al., 1986), colon cancer (Pintauro and Gilbert, 1990), and negative consequences on mineral balance (Schlemmer, 1989) are some of the potential adverse effects of extended consumption of sizable amounts of native and degraded carrageenans. Although there are recognized hazards of dietary carrageenans, there are also benefits such as decreased gastrointestinal tract transit time and decreased luminal pressure due to bulking (de Saint Blanquat and Klein, 1984), and lower serum cholesterol (Shiau and Huang, 1987).

## IMMUNOLOGICAL DISORDERS

Immunocompetence has been shown to be compromised in experimental animals after extended dietary consumption of both native and degraded carrageenans. In earlier studies, only the smaller molecular weight (approximately 20,000) degraded carrageenans were thought to cross the intestinal barrier; however, it was later discovered that there is limited penetration by high-molecular-weight native carrageenans. Although the relatively small amounts of carrageenans crossing the intestinal mucosa may not cause acute toxicity, there may be some chronic repercussions. Carrageenans are biologically active molecules that may cause dose-dependent suppression of lymphocyte responsiveness, thus depressing humoral immunity against heterologous T-cell-dependent antigens. It has also been proposed that macrophages may suffer altered ability to produce immunostimulatory and inhibitory factors. The immunostimulatory factor has been identified as interleukin-1 (IL-1), and the inhibitory factor, although not yet identified, is thought to be a prostaglandin because of its mode of action in depressing humoral antibody production. In young animals that have relatively-permeable intestinal epithelial barriers and not yet fully developed gut-associated lymphoid tissue, there may be heightened risks to dietary exposure to carrageenans (Nicklin and Miller, 1989). Because a new market for carrageenans has been found in infant formulas (Pintauro and Gilbert, 1940), the threat to the immunity of infants through the extended use of these formulas should be monitored.

Carrageenans are also thought to affect immunity through their interactions with the complement system in a series of enzymatic proteins that are found in normal serum and that interact with each



Carrageenans: uses in food and other industries.

other and subsequently join the antigen-antibody complex. It is thought that the carrageenans precipitate the C1 component of the complement system and activate the elements of the complement system involved in antibody-mediated immune lysis, phagocytosis, opsonization, and anaphylaxis (Baker et al., 1986).

The immune responses to dietary carrageenans may be related to the gastrointestinal problems that are also associated with consumption of those seaweed extracts (Nicklin and Miller, 1989).

## GASTROINTESTINAL ABERRATIONS

The key to gastrointestinal ulceration in response to dietary carrageenans appears to be their effect on intestinal macrophages. After carrageenan consumption, lysosomal enzyme release and macrophage necrosis were noted, succeeded by intestinal lining tissue damage and ulceration (Nicklin and Miller, 1989). Gastrointestinal ulceration may also be preceded by degradation of the mucins that protect the intestinal lining from ulceration and act as a barrier to pathogens and toxins (Shiau and Huang, 1987). Mucinase, an enzyme produced by colonic bacteria, is responsible for the degradation of mucins (Shiau and Huang, 1987). Deficiency of a nutrient such as vitamin C, which maintains connective tissue strength and prevents hemorrhagic tendencies in the gut, has also been found to exacerbate the ulceration that ensues from long-term carrageenan use in guinea pigs (Langman et al., 1985).

## CANCER OF THE COLON

The relationship between carrageenans and colon cancer is one that involves the drug-metabolizing enzyme system (DMES) and the promotion of chemically initiated carcinogenesis, as well as intestinal mucosal cell proliferation. The DMES consists of enzymes in two phases: phase I consists of cytochrome P-450, and phase II includes glucuronosyl transferase and glutathione transferase. In the presence of carrageenans, the enzymes in phase I drug metabolism convert precarcinogens such as azoxymethane to their carcinogenic forms, but the phase II enzymes do not further transform the carcinogenic substances to less toxic conjugates.

A 5% ungraded carrageenan diet fed to rats also caused a significant increase in colonic thymidine kinase activity. Escalation in the activity of this enzyme is identified with the rapid colonic cell proliferation characteristic of colon cancer (Pintauro and Gilbert, 1990).

## MINERAL BIOAVAILABILITY

*C. crispus* is a relatively concentrated but insignificant dietary source of minerals such as Ca, Fe, P, K, Cu, and Zn (Table 2), since daily consumption is low. In addition, because seaweed is also high in dietary fiber, there was concern regarding its effect on endogenous mineral bioavailability. However, in vitro experiments conducted to investigate the binding of kappa carrageenan to Ca, Cu, and Zn showed that under the buffered conditions of the intestine, kappa carrageenan does not bind Ca, Cu, or Zn to any nutritionally significant level.

## CARRAGEENANS IN A DIETARY FIBER ROLE

Dietary fiber has long been recognized for its ability to decrease gastrointestinal transit time and reduce the risk of diverticular disease (de Saint Blanquat and Klein, 1984), reduce the risk of colon cancer, and reduce serum cholesterol (Shiau and Huang, 1987). *C. crispus*, which contains 12.3% by weight dietary fiber which is entirely composed of noncellulosic polysaccharide (Holland et al.,

1991), does not, however, perform all the beneficial functions of dietary fiber (Pintauro and Gilbert, 1990).

In research conducted in Taiwan, carrageenans were fed to rats at levels of 5%, 10%, and 15% of a basal diet, and the results were compared with the effects of a 5% cellulose and a fiber-free diet (Shiau and Huang, 1987). The serum cholesterol levels of the carrageenan-fed rats, at all three levels of carrageenan, were significantly lower than those of the fiber-free diet rats, but similar to those of the cellulose-fed rats. The 10% and 15% carrageenan diets produced no significantly greater effect on serum cholesterol than the 5% carrageenan diet, but higher levels of carrageenan did increase colonic mucinase activity, indicative of the degradation of the protective mucosal secretions.

## REFERENCES

- Abbott I, Yale-Dawson E. Key nature series: how to know seaweeds. 2nd ed. Dubuque, Iowa: Williams Brown Co., 1978. Anderson DMW. The carrageenan connection: Can political lobbying undermine food safety decisions? *Br Food J* 1992;94:37-8. Baker KC, Nicklin S, Miller K. The role of carrageenan in complement activation. *Food Chem Toxic* 1986;24:891-5, 1986. Bodeau-Bellion C. Analysis of carrageenan structure. *Physiologie Vegetale*. 1983;21:785-93. Brummel S, Lee K. Soluble hydrocolloids enable fat reduction in process cheese spreads. *J Food Sci* 1990;55:1290-1, 1307 Chapman ARO. Biology of seaweeds: levels of organization. Baltimore: University Park Press, 1979. De Saint Blanquat G, Klein D. Toxicological evaluation of carrageenans: nutritional and digestive effects of carrageenans. *Sciences Des Aliments*. 1984;4:375-88. Descamps O, Langevin P, Combs DH. Physical effects of starch/carrageenan interactions in water and milk. *Food Technol* 1986-40:81-8. Russell EW, Huffman D, Chen C-M, Dylewski D. Development of low-fat ground beef. *Food Technology* 1991;45:64-73. Ferretti A, Judd JT, Taylor P, et al. Ingestion of marine oil reduces excretion of 11-dehydrothromboxane [B.sub.2], an index of intravascular production of thromboxane [A.sub.2]. *Prostaglandins Leukotrienes and Essential Fatty Acids*. 1992;46:271-5. Guiry M, Blunden G. Seaweeds resources in Europe: uses and potential. John Wiley, London, 1991. Gordon-Mills E. Polysaccharides from Australian marine red algae: new methods of characterizing new sources. *Aust J Biotechnol* 4:275-8, 1990. Holland B, Unwin ID, Buss DH. Vegetables, herbs and spices. 5th suppl. to McCance and Widdowson's *The composition of foods*, 4th ed. UK: Royal Society of Chemistry/Ministry of Agriculture Fisheries, and Food, 1991. Irving DEG, Price JH. Modern approaches to taxonomy of red and brown algae. London: Academic Press, 1978. Isaacs F. Irishmoss aquaculture moves from lab to marketplace. *World Aquaculture* 1990;21:95-7. Kailasapathy K, Hourigan JA, Nguyen MH. Effect of casein-carrageenan interactions on yield and sensory qualities of cottage cheese. *Food Aust* 1992;4:30-1, 33-4. Langman JM, Rowland R, Vernon-Roberts B. Carrageenan colitis in the guinea pig: pathological changes and the importance of ascorbic acid deficiency in disease induction. *Aust J Exp Biol Med Sci* 1985-63:545-53. Lobban C, Wynne M. The biology of seaweeds. Botanical Monographs, Vol 17. Berkeley, Los Angeles, California: University of California Press, 1981. Lobban C, Harrison P, Duncan MJ. The Physiological Ecology of Seaweeds. New York: Cambridge University Press, 1985. Luning K. Seaweeds: their environment, biogeography and ecophysiology. New York: John Wiley, 1990. Matsushiro B, Urzua C. Heterogeneity of carrageenans from *Chondrus crispus*. *Phytochemistry* 1991;31:531-4. Mussenden PJ, Keshavarz T, Bucke C. The effects of spore loading on the growth of *Penicillium chrysogenum* immobilized in K-carrageenan. *J Chem Tech Biotechnol* 1991;52:275-82. Nestles Foods Inc. Nestles recipe book. Trinidad, West Indies: Nestles Foods Inc., 1990. Nicklin S, Miller K. Intestinal uptake and immunological effects of carrageenan: current concepts. *Food Addit Contam* 1989;6:425-36. Pintauro SJ, Gilbert SW. The effects of carrageenan on drug-metabolizing enzyme system activities in the guinea pig. *Food Chem Toxic* 1990;28:807-11 Puspitasari, NL, Lee K, Greger JL. Dairy foods: calcium fortification of cottage cheese with hydrocolloid control of bitter flavor defects. *J Dairy Sci*

Carrageenans: uses in food and other industries.

1991;74:1-7. Shiau S-Y, Huang P-L. Effects of Carrageenan on Fecal Mucinase Activity and Serum Cholesterol Level in rats. Nutr Rep Int 1987;35:479-86. Story JA. Lipid research methodology. New York: AR Liss, 1984. Tong C, Hicks K Sulfated polysaccharides inhibit browning of apple juice and diced apples. J Agri Food Chem 1991;39:1719-22.

Dr. Fatma G. Huffman is professor and director of graduate programs in the Department of Dietetics and Nutrition, College of Health, Florida International University. She has served on the faculty at Turkegee University and Howard University. Her research interests include mineral bioavailability from plant products. Correspondence can be addressed to Florida International University Department of Dietetics and Nutrition, University Park, FL 33199

Zara C. Shah received her M.S. degree from Howard University in Washington D.C. She has been accepted to the Ph.D. program at Florida International University. She has worked with Dr. Huffman to study the effects of carrageenan on rat lipid profile.

COPYRIGHT 1995 Williams & Wilkins

*COPYRIGHT 1995 Information Access Company*

You may now print or save this document.

---

**MoneyBackGuarantee** If you buy an article and you are not satisfied with it, let us know and we will refund your money. Please press the "Money Back Guarantee" link for additional information about this policy.

---

Portions of above Copyright © 1997-2000, Northern Light Technology Inc. All rights reserved.

---

[Simple](#)|[PowerSearch](#)|[BusinessSearch](#)|[InvestextSearch](#)|[StockQuotes](#)|[SearchNews](#)|[GeoSearch](#)